[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fEj8J3xSFkxg0f6Go9tTYOBVUKVf8TvavHG4yCMcVCak":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":34,"phaseBuckets":85,"rows":92},"Huazhong University of Science and Technology",[4],239,false,58,14,4819477,30,151,[14,17,20,23,26,28,30,32],{"name":15,"count":16},"Cervical Cancer",15,{"name":18,"count":19},"Gastric Cancer",7,{"name":21,"count":22},"Uterine Cervical Cancer",5,{"name":24,"count":25},"Intubation Complication",4,{"name":27,"count":25},"Uterine Cervical Neoplasm",{"name":29,"count":25},"Postoperative Death",{"name":31,"count":25},"Uterine Cervical Neoplasms",{"name":33,"count":25},"Hepatocellular Carcinoma",[35,40,45,50,55,60,65,70,75,80],{"nctId":36,"briefTitle":37,"date":38,"intervention":39},"NCT04516616","Pd-1 Antibody Combined Neoadjuvant Chemotherapy for Locally Advanced Cervical Cancer","2023-04-30","Cisplatin+Albumin-bound paclitaxel",{"nctId":41,"briefTitle":42,"date":43,"intervention":44},"NCT06516445","SCRT Followed by Camrelizumab Combined With Fluzoparib and Chemotherapy as Neoadjuvant Therapy for LARC","2025-06-28","Camrelizumab",{"nctId":46,"briefTitle":47,"date":48,"intervention":49},"NCT06653621","Effect of Bupivacaine Liposomes or Bupivacaine for Femoral Triangle or Adductor Block on Analgesia After Total Knee Replacement","2025-12-31","Bupivacaine liposome",{"nctId":51,"briefTitle":52,"date":53,"intervention":54},"NCT04723875","Postoperative Adjuvant Chemotherapy in Early-stage Cervical Cancer That Not Meet Criteria of Adjuvant Therapeutic According to NCCN Guideline","2026-01-31","Paclitaxel or docetaxel + Cisplatin or carboplatin",{"nctId":56,"briefTitle":57,"date":58,"intervention":59},"NCT06737341","Bupivacaine Liposomes or Bupivacaine for CMB on Postoperative Analgesia in Laparoscopic Hepatobiliary Pancreatic Surgery","2026-02-01","Bupivacaine Liposomes",{"nctId":61,"briefTitle":62,"date":63,"intervention":64},"NCT06168786","Cadonilimab Combined With Fruquintinib and SBRT as Athird-line and Posterior Line Treatment in Patients With MSS CRC","2026-02-28","Fruquintinib",{"nctId":66,"briefTitle":67,"date":68,"intervention":69},"NCT07085962","Efficacy and Safety of Calculus Bovis Sativus in Adults With MAFLD","2026-03-31","Calculus bovis sativus",{"nctId":71,"briefTitle":72,"date":73,"intervention":74},"NCT06968624","Ketamine for Postherpetic Neuralgia With Depression","2026-04-01","Intravenous Ketamine Infusions",{"nctId":76,"briefTitle":77,"date":78,"intervention":79},"NCT06565910","Bupivacaine Liposome Plus Bupivacaine or Ropivacaine for Pericapsular Nerve Group Block in Hip Arthroplasty (PENG)","2026-06-01","Liposomal bupivacaine plus bupivacaine",{"nctId":81,"briefTitle":82,"date":83,"intervention":84},"NCT06005870","Zanubrutinib Combined With R-CHOP in the Treatment of Newly Diagnosed DLBCL With p53 Protein Expression","2026-07","Zanubrutinib plus RCHOP",[86,87,88,89,90,91],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[93,136,167,195,213,237,255,273,291,316,342,360,386,404,456,490,511,538,588,606,628,646,664,685,730,758,776,794,817,838,865,942,977,999,1027,1045,1063,1081,1108,1126,1144,1162,1180,1206,1230,1253,1279,1305,1330,1348,1366,1392,1410,1428,1446,1475,1511,1537,1555,1580,1598,1624,1650,1668,1694,1723,1741,1759,1786,1804,1827,1845,1863,1889,1907,1932,1957,1983,2001,2019,2044,2070,2088,2134,2152,2177,2202,2225,2243,2267,2285,2316,2334,2360,2413,2452,2474,2496,2518,2545,2568,2592,2618,2640,2658,2683,2701,2727,2751,2774,2792,2817,2835,2853,2878,2896,2923,2950],{"intervention":94,"totalTrials":95,"cells":96},"Iparomlimab and Tuvonralimab",2,{"EARLY_PHASE1":97,"PHASE1":100,"PHASE2":102,"PHASE3":118,"PHASE4":120,"NA":134},{"trials":98,"activeCount":99},[],0,{"trials":101,"activeCount":99},[],{"trials":103,"activeCount":117,"soonestReadout":109},[104],{"nctId":105,"briefTitle":106,"status":107,"phases":108,"primaryCompletion":109,"completion":110,"start":111,"enrollment":112,"conditions":113,"interventions":116},"NCT07502014","A Clinical Study of Iparomlimab and Tuvonralimab Combined With Fruquintinib and Heterogeneous Radiotherapy Versus Fruquintinib as Third-Line and Subsequent-Line Treatment for Metastatic Colorectal Cancer","NOT_YET_RECRUITING",[88],"2028-12-31","2029-12-31","2026-05-01",60,[114,115],"Metastatic Colorectal Cancer (CRC)","mCRC",[94,64],1,{"trials":119,"activeCount":99},[],{"trials":121,"activeCount":117,"soonestReadout":126},[122],{"nctId":123,"briefTitle":124,"status":107,"phases":125,"primaryCompletion":126,"completion":127,"start":78,"enrollment":128,"conditions":129,"interventions":133},"NCT07502027","A Clinical Study of Iparomlimab and Tuvonralimab Combined With SOX Following Heterogeneous Radiotherapy as First-line Treatment for Unresectable Locally Advanced or Metastatic HER2-negative Gastric or Gastroesophageal Junction Adenocarcinoma",[90],"2028-03-31","2029-06-30",55,[130,131,132],"Gastric Cancer (Diagnosis)","Gastric Cancer (GC)","Gastroesophageal Junction Adenocarcinoma",[94],{"trials":135,"activeCount":99},[],{"intervention":137,"totalTrials":95,"cells":138},"Bupivacaine",{"EARLY_PHASE1":139,"PHASE1":141,"PHASE2":143,"PHASE3":145,"PHASE4":147,"NA":165},{"trials":140,"activeCount":99},[],{"trials":142,"activeCount":99},[],{"trials":144,"activeCount":99},[],{"trials":146,"activeCount":99},[],{"trials":148,"activeCount":95,"soonestReadout":48},[149,157],{"nctId":46,"briefTitle":47,"status":107,"phases":150,"primaryCompletion":48,"completion":48,"start":151,"enrollment":152,"conditions":153,"interventions":156},[90],"2024-11-05",144,[154,155],"Knee Arthropathy","Knee Arthritis",[49,137],{"nctId":56,"briefTitle":57,"status":107,"phases":158,"primaryCompletion":58,"completion":58,"start":159,"enrollment":112,"conditions":160,"interventions":164},[90],"2025-10-08",[137,161,162,163],"Ultrasound-Guided","Analgesia, Postoperative","Opioids",[59,137],{"trials":166,"activeCount":99},[],{"intervention":168,"totalTrials":117,"cells":169},"Group A（ liposomal bupivacene）",{"EARLY_PHASE1":170,"PHASE1":172,"PHASE2":174,"PHASE3":176,"PHASE4":178,"NA":193},{"trials":171,"activeCount":99},[],{"trials":173,"activeCount":99},[],{"trials":175,"activeCount":99},[],{"trials":177,"activeCount":99},[],{"trials":179,"activeCount":117,"soonestReadout":184},[180],{"nctId":181,"briefTitle":182,"status":107,"phases":183,"primaryCompletion":184,"completion":184,"start":185,"enrollment":112,"conditions":186,"interventions":191},"NCT07410182","Bupivacaine Liposome Versus Bupivacaine for Ultrasound-Guided Suprascapular Nerve Combined With Axillary Nerve Block in Analgesia After Arthroscopic Shoulder Surgery",[90],"2026-12-30","2026-03-01",[187,188,137,189,190],"Arthroscopic Shoulder Surgery","Ultrasound Guided Nerve Block","Suprascapular Nerve Block","Axillary Nerve Block",[168,192],"Group B（bupivacene）",{"trials":194,"activeCount":99},[],{"intervention":192,"totalTrials":117,"cells":196},{"EARLY_PHASE1":197,"PHASE1":199,"PHASE2":201,"PHASE3":203,"PHASE4":205,"NA":211},{"trials":198,"activeCount":99},[],{"trials":200,"activeCount":99},[],{"trials":202,"activeCount":99},[],{"trials":204,"activeCount":99},[],{"trials":206,"activeCount":117,"soonestReadout":184},[207],{"nctId":181,"briefTitle":182,"status":107,"phases":208,"primaryCompletion":184,"completion":184,"start":185,"enrollment":112,"conditions":209,"interventions":210},[90],[187,188,137,189,190],[168,192],{"trials":212,"activeCount":99},[],{"intervention":74,"totalTrials":117,"cells":214},{"EARLY_PHASE1":215,"PHASE1":217,"PHASE2":219,"PHASE3":221,"PHASE4":223,"NA":235},{"trials":216,"activeCount":99},[],{"trials":218,"activeCount":99},[],{"trials":220,"activeCount":99},[],{"trials":222,"activeCount":99},[],{"trials":224,"activeCount":117,"soonestReadout":73},[225],{"nctId":71,"briefTitle":72,"status":107,"phases":226,"primaryCompletion":73,"completion":78,"start":227,"enrollment":228,"conditions":229,"interventions":232},[90],"2025-06-15",50,[230,231],"Depression Disorders","Herpetic Neuralgia",[74,233,234],"Intravenous normal saline","Oral Duloxetine 60mg",{"trials":236,"activeCount":99},[],{"intervention":233,"totalTrials":117,"cells":238},{"EARLY_PHASE1":239,"PHASE1":241,"PHASE2":243,"PHASE3":245,"PHASE4":247,"NA":253},{"trials":240,"activeCount":99},[],{"trials":242,"activeCount":99},[],{"trials":244,"activeCount":99},[],{"trials":246,"activeCount":99},[],{"trials":248,"activeCount":117,"soonestReadout":73},[249],{"nctId":71,"briefTitle":72,"status":107,"phases":250,"primaryCompletion":73,"completion":78,"start":227,"enrollment":228,"conditions":251,"interventions":252},[90],[230,231],[74,233,234],{"trials":254,"activeCount":99},[],{"intervention":234,"totalTrials":117,"cells":256},{"EARLY_PHASE1":257,"PHASE1":259,"PHASE2":261,"PHASE3":263,"PHASE4":265,"NA":271},{"trials":258,"activeCount":99},[],{"trials":260,"activeCount":99},[],{"trials":262,"activeCount":99},[],{"trials":264,"activeCount":99},[],{"trials":266,"activeCount":117,"soonestReadout":73},[267],{"nctId":71,"briefTitle":72,"status":107,"phases":268,"primaryCompletion":73,"completion":78,"start":227,"enrollment":228,"conditions":269,"interventions":270},[90],[230,231],[74,233,234],{"trials":272,"activeCount":99},[],{"intervention":49,"totalTrials":117,"cells":274},{"EARLY_PHASE1":275,"PHASE1":277,"PHASE2":279,"PHASE3":281,"PHASE4":283,"NA":289},{"trials":276,"activeCount":99},[],{"trials":278,"activeCount":99},[],{"trials":280,"activeCount":99},[],{"trials":282,"activeCount":99},[],{"trials":284,"activeCount":117,"soonestReadout":48},[285],{"nctId":46,"briefTitle":47,"status":107,"phases":286,"primaryCompletion":48,"completion":48,"start":151,"enrollment":152,"conditions":287,"interventions":288},[90],[154,155],[49,137],{"trials":290,"activeCount":99},[],{"intervention":79,"totalTrials":117,"cells":292},{"EARLY_PHASE1":293,"PHASE1":295,"PHASE2":297,"PHASE3":299,"PHASE4":301,"NA":314},{"trials":294,"activeCount":99},[],{"trials":296,"activeCount":99},[],{"trials":298,"activeCount":99},[],{"trials":300,"activeCount":99},[],{"trials":302,"activeCount":117,"soonestReadout":78},[303],{"nctId":76,"briefTitle":77,"status":304,"phases":305,"primaryCompletion":78,"completion":306,"start":307,"enrollment":112,"conditions":308,"interventions":312},"RECRUITING",[90],"2026-07-01","2024-12-04",[309,310,311],"Femoral Neck Fractures","Femur Head Necrosis","Hip Fractures",[79,313],"Ropivacaine",{"trials":315,"activeCount":99},[],{"intervention":317,"totalTrials":117,"cells":318},"SGLT2i+Metformin+Cofrogliptin",{"EARLY_PHASE1":319,"PHASE1":321,"PHASE2":323,"PHASE3":325,"PHASE4":327,"NA":340},{"trials":320,"activeCount":99},[],{"trials":322,"activeCount":99},[],{"trials":324,"activeCount":99},[],{"trials":326,"activeCount":99},[],{"trials":328,"activeCount":117,"soonestReadout":333},[329],{"nctId":330,"briefTitle":331,"status":304,"phases":332,"primaryCompletion":333,"completion":184,"start":334,"enrollment":335,"conditions":336,"interventions":338},"NCT07019012","Cofrogliptin Once Every 2 Weeks as Add-on Therapy to Metformin and Dapagliflozin Versus Daily Linagliptin in Patients With Type 2 Diabetes.",[90],"2026-10-30","2025-07-30",170,[337],"T2DM",[317,339],"SGLT2i+Metformin+Linagliptin",{"trials":341,"activeCount":99},[],{"intervention":339,"totalTrials":117,"cells":343},{"EARLY_PHASE1":344,"PHASE1":346,"PHASE2":348,"PHASE3":350,"PHASE4":352,"NA":358},{"trials":345,"activeCount":99},[],{"trials":347,"activeCount":99},[],{"trials":349,"activeCount":99},[],{"trials":351,"activeCount":99},[],{"trials":353,"activeCount":117,"soonestReadout":333},[354],{"nctId":330,"briefTitle":331,"status":304,"phases":355,"primaryCompletion":333,"completion":184,"start":334,"enrollment":335,"conditions":356,"interventions":357},[90],[337],[317,339],{"trials":359,"activeCount":99},[],{"intervention":361,"totalTrials":117,"cells":362},"Tirzepatide",{"EARLY_PHASE1":363,"PHASE1":365,"PHASE2":367,"PHASE3":369,"PHASE4":371,"NA":384},{"trials":364,"activeCount":99},[],{"trials":366,"activeCount":99},[],{"trials":368,"activeCount":99},[],{"trials":370,"activeCount":99},[],{"trials":372,"activeCount":117,"soonestReadout":377},[373],{"nctId":374,"briefTitle":375,"status":107,"phases":376,"primaryCompletion":377,"completion":377,"start":378,"enrollment":379,"conditions":380,"interventions":383},"NCT07555730","AI-assisted Multi-domain Lifestyle Versus Tirzepatide for Weight Loss Maintenance in Adults With Type 2 Diabetes (AIM-MAINTAIN)",[90],"2028-09-30","2026-04-30",400,[381,382],"Overweight or Obesity; Type 2 Diabetes","Weight Loss Maintenance",[361],{"trials":385,"activeCount":99},[],{"intervention":59,"totalTrials":117,"cells":387},{"EARLY_PHASE1":388,"PHASE1":390,"PHASE2":392,"PHASE3":394,"PHASE4":396,"NA":402},{"trials":389,"activeCount":99},[],{"trials":391,"activeCount":99},[],{"trials":393,"activeCount":99},[],{"trials":395,"activeCount":99},[],{"trials":397,"activeCount":117,"soonestReadout":58},[398],{"nctId":56,"briefTitle":57,"status":107,"phases":399,"primaryCompletion":58,"completion":58,"start":159,"enrollment":112,"conditions":400,"interventions":401},[90],[137,161,162,163],[59,137],{"trials":403,"activeCount":99},[],{"intervention":313,"totalTrials":25,"cells":405},{"EARLY_PHASE1":406,"PHASE1":408,"PHASE2":410,"PHASE3":412,"PHASE4":414,"NA":420},{"trials":407,"activeCount":99},[],{"trials":409,"activeCount":99},[],{"trials":411,"activeCount":99},[],{"trials":413,"activeCount":99},[],{"trials":415,"activeCount":117,"soonestReadout":78},[416],{"nctId":76,"briefTitle":77,"status":304,"phases":417,"primaryCompletion":78,"completion":306,"start":307,"enrollment":112,"conditions":418,"interventions":419},[90],[309,310,311],[79,313],{"trials":421,"activeCount":99},[422,433,445],{"nctId":423,"briefTitle":424,"status":425,"phases":426,"primaryCompletion":427,"completion":428,"start":429,"enrollment":228,"conditions":430,"interventions":432},"NCT03279679","Comparison Between Costoclavicular and Paracoracoid Ultrasound-guided Infraclavicular Block for Forearm Surgery","UNKNOWN",[91],"2018-06","2018-07","2017-10",[431],"Brachial Plexus Block",[313],{"nctId":434,"briefTitle":435,"status":436,"phases":437,"primaryCompletion":438,"completion":439,"start":440,"enrollment":441,"conditions":442,"interventions":444},"NCT02512471","The Minimum Effective Volume of Ropivacaine in Ultrasound-guided Supraclavicular Block","COMPLETED",[91],"2015-09","2015-10","2015-05",114,[443],"Supraclavicular Brachial Plexus Block",[313],{"nctId":446,"briefTitle":447,"status":436,"phases":448,"primaryCompletion":449,"completion":449,"start":450,"enrollment":451,"conditions":452,"interventions":454},"NCT06688136","QLESP Block Versus Periarticular Infiltration for Postoperative Analgesia in Hip Surgery",[91],"2025-09-05","2024-11-18",68,[453],"Regional Anaesthesia",[455],"ropivacaine",{"intervention":457,"totalTrials":95,"cells":458},"Adjuvant chemotherapy",{"EARLY_PHASE1":459,"PHASE1":461,"PHASE2":463,"PHASE3":465,"PHASE4":486,"NA":488},{"trials":460,"activeCount":99},[],{"trials":462,"activeCount":99},[],{"trials":464,"activeCount":99},[],{"trials":466,"activeCount":117,"soonestReadout":481},[467,477],{"nctId":468,"briefTitle":469,"status":436,"phases":470,"primaryCompletion":471,"completion":471,"start":472,"enrollment":473,"conditions":474,"interventions":475},"NCT03308591","Clinical Efficacy of the Neoadjuvant Chemotherapy for IB2 and IIA2 Stage Cervical Cancer Patients",[89],"2022-02-01","2016-01-11",774,[27,15,21],[476,457],"NACT",{"nctId":478,"briefTitle":479,"status":304,"phases":480,"primaryCompletion":481,"completion":481,"start":482,"enrollment":483,"conditions":484,"interventions":485},"NCT04733820","Clinical Efficacy of Adjuvant Chemotherapy in Patients With Locally Advanced Cervical Cancer Who Did Not Meet the NCCN Guidelines for Adjuvant Treatment After NACT Combined With Surgery",[89],"2028-02-01","2021-02-01",340,[31,15],[457],{"trials":487,"activeCount":99},[],{"trials":489,"activeCount":99},[],{"intervention":54,"totalTrials":117,"cells":491},{"EARLY_PHASE1":492,"PHASE1":494,"PHASE2":496,"PHASE3":498,"PHASE4":507,"NA":509},{"trials":493,"activeCount":99},[],{"trials":495,"activeCount":99},[],{"trials":497,"activeCount":99},[],{"trials":499,"activeCount":117,"soonestReadout":53},[500],{"nctId":51,"briefTitle":52,"status":501,"phases":502,"primaryCompletion":53,"completion":53,"start":503,"enrollment":504,"conditions":505,"interventions":506},"ACTIVE_NOT_RECRUITING",[89],"2021-01-28",306,[31,15],[54],{"trials":508,"activeCount":99},[],{"trials":510,"activeCount":99},[],{"intervention":64,"totalTrials":95,"cells":512},{"EARLY_PHASE1":513,"PHASE1":515,"PHASE2":517,"PHASE3":532,"PHASE4":534,"NA":536},{"trials":514,"activeCount":99},[],{"trials":516,"activeCount":99},[],{"trials":518,"activeCount":95,"soonestReadout":63},[519,523],{"nctId":105,"briefTitle":106,"status":107,"phases":520,"primaryCompletion":109,"completion":110,"start":111,"enrollment":112,"conditions":521,"interventions":522},[88],[114,115],[94,64],{"nctId":61,"briefTitle":62,"status":304,"phases":524,"primaryCompletion":63,"completion":525,"start":526,"enrollment":527,"conditions":528,"interventions":530},[88],"2027-02-28","2023-06-20",40,[529],"Colorectal Cancer",[64,531],"Cadonilimab",{"trials":533,"activeCount":99},[],{"trials":535,"activeCount":99},[],{"trials":537,"activeCount":99},[],{"intervention":44,"totalTrials":539,"cells":540},3,{"EARLY_PHASE1":541,"PHASE1":543,"PHASE2":545,"PHASE3":582,"PHASE4":584,"NA":586},{"trials":542,"activeCount":99},[],{"trials":544,"activeCount":99},[],{"trials":546,"activeCount":117,"soonestReadout":43},[547,561,573],{"nctId":548,"briefTitle":549,"status":425,"phases":550,"primaryCompletion":551,"completion":552,"start":553,"enrollment":11,"conditions":554,"interventions":556},"NCT05142865","Camrelizumab Combined With Chemotherapy and Apatinib for Extrapulmonary Neuroendocrine Carcinomas",[88],"2024-01-14","2024-12-31","2022-01-14",[555],"Advanced or Metastatic EP-NEC",[44,557,558,559,560],"Etoposide","Carboplatin","Cisplatin","Apatinib",{"nctId":562,"briefTitle":563,"status":425,"phases":564,"primaryCompletion":565,"completion":566,"start":567,"enrollment":11,"conditions":568,"interventions":571},"NCT05320081","Camrelizumab Combined With CD30 CAR-T in the Treatment of Relapsed\u002FRefractory CD30+ Lymphoma",[88],"2023-12-31","2024-06-30","2021-11-30",[569,570],"Lymphoma","Relapse\u002FRecurrence",[572,44],"CD30 CAR-T",{"nctId":41,"briefTitle":42,"status":304,"phases":574,"primaryCompletion":43,"completion":575,"start":576,"enrollment":577,"conditions":578,"interventions":579},[88],"2026-06-28","2023-06-28",33,[529],[44,580,581],"Fluzoparib","CAPEOX",{"trials":583,"activeCount":99},[],{"trials":585,"activeCount":99},[],{"trials":587,"activeCount":99},[],{"intervention":531,"totalTrials":117,"cells":589},{"EARLY_PHASE1":590,"PHASE1":592,"PHASE2":594,"PHASE3":600,"PHASE4":602,"NA":604},{"trials":591,"activeCount":99},[],{"trials":593,"activeCount":99},[],{"trials":595,"activeCount":117,"soonestReadout":63},[596],{"nctId":61,"briefTitle":62,"status":304,"phases":597,"primaryCompletion":63,"completion":525,"start":526,"enrollment":527,"conditions":598,"interventions":599},[88],[529],[64,531],{"trials":601,"activeCount":99},[],{"trials":603,"activeCount":99},[],{"trials":605,"activeCount":99},[],{"intervention":84,"totalTrials":117,"cells":607},{"EARLY_PHASE1":608,"PHASE1":610,"PHASE2":612,"PHASE3":622,"PHASE4":624,"NA":626},{"trials":609,"activeCount":99},[],{"trials":611,"activeCount":99},[],{"trials":613,"activeCount":117,"soonestReadout":83},[614],{"nctId":81,"briefTitle":82,"status":304,"phases":615,"primaryCompletion":83,"completion":616,"start":617,"enrollment":618,"conditions":619,"interventions":621},[88],"2026-12","2022-11-26",41,[620],"Diffuse Large B Cell Lymphoma",[84],{"trials":623,"activeCount":99},[],{"trials":625,"activeCount":99},[],{"trials":627,"activeCount":99},[],{"intervention":580,"totalTrials":117,"cells":629},{"EARLY_PHASE1":630,"PHASE1":632,"PHASE2":634,"PHASE3":640,"PHASE4":642,"NA":644},{"trials":631,"activeCount":99},[],{"trials":633,"activeCount":99},[],{"trials":635,"activeCount":117,"soonestReadout":43},[636],{"nctId":41,"briefTitle":42,"status":304,"phases":637,"primaryCompletion":43,"completion":575,"start":576,"enrollment":577,"conditions":638,"interventions":639},[88],[529],[44,580,581],{"trials":641,"activeCount":99},[],{"trials":643,"activeCount":99},[],{"trials":645,"activeCount":99},[],{"intervention":581,"totalTrials":117,"cells":647},{"EARLY_PHASE1":648,"PHASE1":650,"PHASE2":652,"PHASE3":658,"PHASE4":660,"NA":662},{"trials":649,"activeCount":99},[],{"trials":651,"activeCount":99},[],{"trials":653,"activeCount":117,"soonestReadout":43},[654],{"nctId":41,"briefTitle":42,"status":304,"phases":655,"primaryCompletion":43,"completion":575,"start":576,"enrollment":577,"conditions":656,"interventions":657},[88],[529],[44,580,581],{"trials":659,"activeCount":99},[],{"trials":661,"activeCount":99},[],{"trials":663,"activeCount":99},[],{"intervention":39,"totalTrials":117,"cells":665},{"EARLY_PHASE1":666,"PHASE1":668,"PHASE2":670,"PHASE3":679,"PHASE4":681,"NA":683},{"trials":667,"activeCount":99},[],{"trials":669,"activeCount":99},[],{"trials":671,"activeCount":117,"soonestReadout":38},[672],{"nctId":36,"briefTitle":37,"status":501,"phases":673,"primaryCompletion":38,"completion":674,"start":675,"enrollment":676,"conditions":677,"interventions":678},[88],"2028-07-01","2020-12-01",85,[27,21,15],[39],{"trials":680,"activeCount":99},[],{"trials":682,"activeCount":99},[],{"trials":684,"activeCount":99},[],{"intervention":686,"totalTrials":539,"cells":687},"Vitamin D3",{"EARLY_PHASE1":688,"PHASE1":690,"PHASE2":692,"PHASE3":694,"PHASE4":696,"NA":698},{"trials":689,"activeCount":99},[],{"trials":691,"activeCount":99},[],{"trials":693,"activeCount":99},[],{"trials":695,"activeCount":99},[],{"trials":697,"activeCount":99},[],{"trials":699,"activeCount":95,"soonestReadout":704},[700,710,720],{"nctId":701,"briefTitle":702,"status":304,"phases":703,"primaryCompletion":704,"completion":704,"start":705,"enrollment":706,"conditions":707,"interventions":709},"NCT06553729","Effects of Vitamin D and Prebiotic Supplementation on Glucose Control During Pregnancy",[91],"2026-12-31","2025-02-24",500,[708],"Glucose Intolerance During Pregnancy",[686],{"nctId":711,"briefTitle":712,"status":436,"phases":713,"primaryCompletion":552,"completion":714,"start":715,"enrollment":716,"conditions":717,"interventions":719},"NCT06351566","Effects of Vitamin D3 and Prebiotics Supplementation on Cardiovascular Risk Factors in Patients With Type 2 Diabetes",[91],"2025-08-31","2024-04-25",190,[718],"Diabetes Mellitus, Type 2",[686],{"nctId":721,"briefTitle":722,"status":304,"phases":723,"primaryCompletion":724,"completion":725,"start":726,"enrollment":727,"conditions":728,"interventions":729},"NCT06861062","Effects of Vitamin D3 and Yeast Beta-Glucan Supplementation on Glycemic Control and Cardiovascular Disease Risk in Patients With Type 2 Diabetes",[91],"2030-12-31","2032-12-31","2025-04-08",2500,[718],[686],{"intervention":731,"totalTrials":117,"cells":732},"Liposomal bupivacaine",{"EARLY_PHASE1":733,"PHASE1":735,"PHASE2":737,"PHASE3":739,"PHASE4":741,"NA":743},{"trials":734,"activeCount":99},[],{"trials":736,"activeCount":99},[],{"trials":738,"activeCount":99},[],{"trials":740,"activeCount":99},[],{"trials":742,"activeCount":99},[],{"trials":744,"activeCount":117,"soonestReadout":333},[745],{"nctId":746,"briefTitle":747,"status":304,"phases":748,"primaryCompletion":333,"completion":184,"start":749,"enrollment":750,"conditions":751,"interventions":755},"NCT07509866","Liposomal Bupivacaine Versus Ropivacaine With Perineural Dexamethasone or Dexmedetomidine as Adjuncts for Adductor Canal Block Combined With IPACK Block in Total Knee Arthroplasty",[91],"2026-04-09",90,[752,753,313,754],"Total Knee Anthroplasty","Nerve Block","Liposomal Bupivacaine",[731,756,757],"Ropivacaine with Perineural Dexamethasone","Ropivacaine with Perineural Dexmedetomidine",{"intervention":756,"totalTrials":117,"cells":759},{"EARLY_PHASE1":760,"PHASE1":762,"PHASE2":764,"PHASE3":766,"PHASE4":768,"NA":770},{"trials":761,"activeCount":99},[],{"trials":763,"activeCount":99},[],{"trials":765,"activeCount":99},[],{"trials":767,"activeCount":99},[],{"trials":769,"activeCount":99},[],{"trials":771,"activeCount":117,"soonestReadout":333},[772],{"nctId":746,"briefTitle":747,"status":304,"phases":773,"primaryCompletion":333,"completion":184,"start":749,"enrollment":750,"conditions":774,"interventions":775},[91],[752,753,313,754],[731,756,757],{"intervention":757,"totalTrials":117,"cells":777},{"EARLY_PHASE1":778,"PHASE1":780,"PHASE2":782,"PHASE3":784,"PHASE4":786,"NA":788},{"trials":779,"activeCount":99},[],{"trials":781,"activeCount":99},[],{"trials":783,"activeCount":99},[],{"trials":785,"activeCount":99},[],{"trials":787,"activeCount":99},[],{"trials":789,"activeCount":117,"soonestReadout":333},[790],{"nctId":746,"briefTitle":747,"status":304,"phases":791,"primaryCompletion":333,"completion":184,"start":749,"enrollment":750,"conditions":792,"interventions":793},[91],[752,753,313,754],[731,756,757],{"intervention":795,"totalTrials":117,"cells":796},"Stapokibart",{"EARLY_PHASE1":797,"PHASE1":799,"PHASE2":801,"PHASE3":803,"PHASE4":805,"NA":807},{"trials":798,"activeCount":99},[],{"trials":800,"activeCount":99},[],{"trials":802,"activeCount":99},[],{"trials":804,"activeCount":99},[],{"trials":806,"activeCount":99},[],{"trials":808,"activeCount":117,"soonestReadout":704},[809],{"nctId":810,"briefTitle":811,"status":107,"phases":812,"primaryCompletion":704,"completion":525,"start":813,"enrollment":750,"conditions":814,"interventions":816},"NCT07240376","Efficacy and Safety of Stapokibart in Non-Allergic Rhinitis With Eosinophilia Syndrome",[91],"2025-11-25",[815],"Non-Allergic Rhinitis With Eosinophilia Syndrome",[795],{"intervention":69,"totalTrials":117,"cells":818},{"EARLY_PHASE1":819,"PHASE1":821,"PHASE2":823,"PHASE3":825,"PHASE4":827,"NA":829},{"trials":820,"activeCount":99},[],{"trials":822,"activeCount":99},[],{"trials":824,"activeCount":99},[],{"trials":826,"activeCount":99},[],{"trials":828,"activeCount":99},[],{"trials":830,"activeCount":117,"soonestReadout":68},[831],{"nctId":66,"briefTitle":67,"status":107,"phases":832,"primaryCompletion":68,"completion":833,"start":834,"enrollment":527,"conditions":835,"interventions":837},[91],"2026-07-31","2025-08-01",[836],"Metabolic Dysfunction-associated Fatty Liver Disease",[69],{"intervention":839,"totalTrials":117,"cells":840},"Anesthetic Agents",{"EARLY_PHASE1":841,"PHASE1":843,"PHASE2":845,"PHASE3":847,"PHASE4":849,"NA":851},{"trials":842,"activeCount":99},[],{"trials":844,"activeCount":99},[],{"trials":846,"activeCount":99},[],{"trials":848,"activeCount":99},[],{"trials":850,"activeCount":99},[],{"trials":852,"activeCount":117,"soonestReadout":857},[853],{"nctId":854,"briefTitle":855,"status":304,"phases":856,"primaryCompletion":857,"completion":858,"start":859,"enrollment":860,"conditions":861,"interventions":864},"NCT07410702","Correlating EEG Dynamics With Consciousness Alteration Under Anesthesia",[],"2026-10-20","2027-02-20","2026-02-10",250,[862,863],"Altered State of Consciousness","General Anesthetics",[839],{"intervention":866,"totalTrials":22,"cells":867},"Sevoflurane",{"EARLY_PHASE1":868,"PHASE1":870,"PHASE2":872,"PHASE3":874,"PHASE4":876,"NA":940},{"trials":869,"activeCount":99},[],{"trials":871,"activeCount":99},[],{"trials":873,"activeCount":99},[],{"trials":875,"activeCount":99},[],{"trials":877,"activeCount":99},[878,895,906,918,930],{"nctId":879,"briefTitle":880,"status":425,"phases":881,"primaryCompletion":882,"completion":882,"start":883,"enrollment":884,"conditions":885,"interventions":887},"NCT03135795","The Epigenetic Modification in OPRM1 on Postoperative Analgesia and Side Effect Induced by Sufentanil",[90],"2017-05-31","2017-02-06",100,[886],"Epigenetics",[888,889,890,891,892,893,894],"Sufentanil","dexmedetomidine","propofol","Rocuronium","sevoflurane","remifentanil","Parecoxib",{"nctId":896,"briefTitle":897,"status":425,"phases":898,"primaryCompletion":899,"start":900,"enrollment":706,"conditions":901,"interventions":904},"NCT01995214","Sevoflurane and Propofol Anesthesia on Postoperative Delirium",[90],"2013-12","2013-06",[902,903],"General Anesthesia","Geriatric Patient",[905,866],"Propofol",{"nctId":907,"briefTitle":908,"status":436,"phases":909,"primaryCompletion":910,"completion":910,"start":911,"enrollment":750,"conditions":912,"interventions":915},"NCT01084200","Comparison of Sevoflurane, Propofol, and Sevoflurane Plus Propofol for Maintenance of Anaesthesia",[90],"2010-01","2009-09",[913,914],"Laparoscopic Surgery","Hysteroscopic Surgery",[916,866,917],"Propofol for maintenance","Sevoflurane+Propofol",{"nctId":919,"briefTitle":920,"status":436,"phases":921,"primaryCompletion":922,"completion":923,"start":924,"enrollment":925,"conditions":926,"interventions":928},"NCT01705743","Minimum Alveolar Concentration of Sevoflurane With Nitrous Oxide Inducing Isoelectric EEG",[90],"2013-09","2013-10","2012-09",76,[927,902],"Middle Aged Patients",[929,866],"Sevoflurane+Nitrous oxide",{"nctId":931,"briefTitle":932,"status":436,"phases":933,"primaryCompletion":934,"completion":935,"start":936,"enrollment":937,"conditions":938,"interventions":939},"NCT01662622","Minimal Alveolar Concentration of Sevoflurane Inducing Isoelectric Electroencephalogram",[90],"2012-05","2012-07","2012-03",31,[927,866,902],[866],{"trials":941,"activeCount":99},[],{"intervention":890,"totalTrials":539,"cells":943},{"EARLY_PHASE1":944,"PHASE1":946,"PHASE2":948,"PHASE3":950,"PHASE4":952,"NA":975},{"trials":945,"activeCount":99},[],{"trials":947,"activeCount":99},[],{"trials":949,"activeCount":99},[],{"trials":951,"activeCount":99},[],{"trials":953,"activeCount":99},[954,958,962],{"nctId":879,"briefTitle":880,"status":425,"phases":955,"primaryCompletion":882,"completion":882,"start":883,"enrollment":884,"conditions":956,"interventions":957},[90],[886],[888,889,890,891,892,893,894],{"nctId":896,"briefTitle":897,"status":425,"phases":959,"primaryCompletion":899,"start":900,"enrollment":706,"conditions":960,"interventions":961},[90],[902,903],[905,866],{"nctId":963,"briefTitle":964,"status":425,"phases":965,"primaryCompletion":966,"completion":967,"start":968,"enrollment":112,"conditions":969,"interventions":972},"NCT02213718","The Effect of Desflurane on Myocardial Function in Patients Undergoing Coronary Artery Bypass Grafting",[90],"2017-01","2017-06","2014-07",[970,971],"Coronary Artery Bypass Graft Redo","General Anesthetic Drug Adverse Reaction",[973,890,974],"Desflurane","sufentanil",{"trials":976,"activeCount":99},[],{"intervention":888,"totalTrials":95,"cells":978},{"EARLY_PHASE1":979,"PHASE1":981,"PHASE2":983,"PHASE3":985,"PHASE4":987,"NA":997},{"trials":980,"activeCount":99},[],{"trials":982,"activeCount":99},[],{"trials":984,"activeCount":99},[],{"trials":986,"activeCount":99},[],{"trials":988,"activeCount":99},[989,993],{"nctId":879,"briefTitle":880,"status":425,"phases":990,"primaryCompletion":882,"completion":882,"start":883,"enrollment":884,"conditions":991,"interventions":992},[90],[886],[888,889,890,891,892,893,894],{"nctId":963,"briefTitle":964,"status":425,"phases":994,"primaryCompletion":966,"completion":967,"start":968,"enrollment":112,"conditions":995,"interventions":996},[90],[970,971],[973,890,974],{"trials":998,"activeCount":99},[],{"intervention":1000,"totalTrials":117,"cells":1001},"Group P+P",{"EARLY_PHASE1":1002,"PHASE1":1004,"PHASE2":1006,"PHASE3":1008,"PHASE4":1010,"NA":1025},{"trials":1003,"activeCount":99},[],{"trials":1005,"activeCount":99},[],{"trials":1007,"activeCount":99},[],{"trials":1009,"activeCount":99},[],{"trials":1011,"activeCount":99},[1012],{"nctId":1013,"briefTitle":1014,"status":436,"phases":1015,"primaryCompletion":1016,"completion":1017,"start":910,"enrollment":1018,"conditions":1019,"interventions":1021},"NCT01304953","Tropisetron on Postoperative Pain",[90],"2010-11","2010-12",296,[1020],"Pain, Postoperative",[1000,1022,1023,1024],"Group P+T","Group S+P","Group S+T",{"trials":1026,"activeCount":99},[],{"intervention":1022,"totalTrials":117,"cells":1028},{"EARLY_PHASE1":1029,"PHASE1":1031,"PHASE2":1033,"PHASE3":1035,"PHASE4":1037,"NA":1043},{"trials":1030,"activeCount":99},[],{"trials":1032,"activeCount":99},[],{"trials":1034,"activeCount":99},[],{"trials":1036,"activeCount":99},[],{"trials":1038,"activeCount":99},[1039],{"nctId":1013,"briefTitle":1014,"status":436,"phases":1040,"primaryCompletion":1016,"completion":1017,"start":910,"enrollment":1018,"conditions":1041,"interventions":1042},[90],[1020],[1000,1022,1023,1024],{"trials":1044,"activeCount":99},[],{"intervention":1023,"totalTrials":117,"cells":1046},{"EARLY_PHASE1":1047,"PHASE1":1049,"PHASE2":1051,"PHASE3":1053,"PHASE4":1055,"NA":1061},{"trials":1048,"activeCount":99},[],{"trials":1050,"activeCount":99},[],{"trials":1052,"activeCount":99},[],{"trials":1054,"activeCount":99},[],{"trials":1056,"activeCount":99},[1057],{"nctId":1013,"briefTitle":1014,"status":436,"phases":1058,"primaryCompletion":1016,"completion":1017,"start":910,"enrollment":1018,"conditions":1059,"interventions":1060},[90],[1020],[1000,1022,1023,1024],{"trials":1062,"activeCount":99},[],{"intervention":1024,"totalTrials":117,"cells":1064},{"EARLY_PHASE1":1065,"PHASE1":1067,"PHASE2":1069,"PHASE3":1071,"PHASE4":1073,"NA":1079},{"trials":1066,"activeCount":99},[],{"trials":1068,"activeCount":99},[],{"trials":1070,"activeCount":99},[],{"trials":1072,"activeCount":99},[],{"trials":1074,"activeCount":99},[1075],{"nctId":1013,"briefTitle":1014,"status":436,"phases":1076,"primaryCompletion":1016,"completion":1017,"start":910,"enrollment":1018,"conditions":1077,"interventions":1078},[90],[1020],[1000,1022,1023,1024],{"trials":1080,"activeCount":99},[],{"intervention":1082,"totalTrials":117,"cells":1083},"Omega-3 Fatty Acid-Based Parenteral Nutrition",{"EARLY_PHASE1":1084,"PHASE1":1086,"PHASE2":1088,"PHASE3":1090,"PHASE4":1092,"NA":1106},{"trials":1085,"activeCount":99},[],{"trials":1087,"activeCount":99},[],{"trials":1089,"activeCount":99},[],{"trials":1091,"activeCount":99},[],{"trials":1093,"activeCount":99},[1094],{"nctId":1095,"briefTitle":1096,"status":436,"phases":1097,"primaryCompletion":922,"completion":1098,"start":1099,"enrollment":1100,"conditions":1101,"interventions":1104},"NCT02321202","Omega-3 Fatty Acid-Based Parenteral Nutrition Improves Postoperative Recovery for Cirrhotic Patients With Liver Cancer",[90],"2013-11","2010-03",320,[1102,1103],"Liver Cancer","Cirrhosis",[1082,1105],"Structolipid",{"trials":1107,"activeCount":99},[],{"intervention":1105,"totalTrials":117,"cells":1109},{"EARLY_PHASE1":1110,"PHASE1":1112,"PHASE2":1114,"PHASE3":1116,"PHASE4":1118,"NA":1124},{"trials":1111,"activeCount":99},[],{"trials":1113,"activeCount":99},[],{"trials":1115,"activeCount":99},[],{"trials":1117,"activeCount":99},[],{"trials":1119,"activeCount":99},[1120],{"nctId":1095,"briefTitle":1096,"status":436,"phases":1121,"primaryCompletion":922,"completion":1098,"start":1099,"enrollment":1100,"conditions":1122,"interventions":1123},[90],[1102,1103],[1082,1105],{"trials":1125,"activeCount":99},[],{"intervention":891,"totalTrials":117,"cells":1127},{"EARLY_PHASE1":1128,"PHASE1":1130,"PHASE2":1132,"PHASE3":1134,"PHASE4":1136,"NA":1142},{"trials":1129,"activeCount":99},[],{"trials":1131,"activeCount":99},[],{"trials":1133,"activeCount":99},[],{"trials":1135,"activeCount":99},[],{"trials":1137,"activeCount":99},[1138],{"nctId":879,"briefTitle":880,"status":425,"phases":1139,"primaryCompletion":882,"completion":882,"start":883,"enrollment":884,"conditions":1140,"interventions":1141},[90],[886],[888,889,890,891,892,893,894],{"trials":1143,"activeCount":99},[],{"intervention":893,"totalTrials":117,"cells":1145},{"EARLY_PHASE1":1146,"PHASE1":1148,"PHASE2":1150,"PHASE3":1152,"PHASE4":1154,"NA":1160},{"trials":1147,"activeCount":99},[],{"trials":1149,"activeCount":99},[],{"trials":1151,"activeCount":99},[],{"trials":1153,"activeCount":99},[],{"trials":1155,"activeCount":99},[1156],{"nctId":879,"briefTitle":880,"status":425,"phases":1157,"primaryCompletion":882,"completion":882,"start":883,"enrollment":884,"conditions":1158,"interventions":1159},[90],[886],[888,889,890,891,892,893,894],{"trials":1161,"activeCount":99},[],{"intervention":894,"totalTrials":117,"cells":1163},{"EARLY_PHASE1":1164,"PHASE1":1166,"PHASE2":1168,"PHASE3":1170,"PHASE4":1172,"NA":1178},{"trials":1165,"activeCount":99},[],{"trials":1167,"activeCount":99},[],{"trials":1169,"activeCount":99},[],{"trials":1171,"activeCount":99},[],{"trials":1173,"activeCount":99},[1174],{"nctId":879,"briefTitle":880,"status":425,"phases":1175,"primaryCompletion":882,"completion":882,"start":883,"enrollment":884,"conditions":1176,"interventions":1177},[90],[886],[888,889,890,891,892,893,894],{"trials":1179,"activeCount":99},[],{"intervention":1181,"totalTrials":117,"cells":1182},"Sorafenib",{"EARLY_PHASE1":1183,"PHASE1":1185,"PHASE2":1187,"PHASE3":1189,"PHASE4":1191,"NA":1204},{"trials":1184,"activeCount":99},[],{"trials":1186,"activeCount":99},[],{"trials":1188,"activeCount":99},[],{"trials":1190,"activeCount":99},[],{"trials":1192,"activeCount":99},[1193],{"nctId":1194,"briefTitle":1195,"status":425,"phases":1196,"primaryCompletion":1197,"completion":1198,"start":1199,"enrollment":1200,"conditions":1201,"interventions":1203},"NCT03178656","A Trial to Compare Surgery With Sorafenib for Hepatic Celluler Cancer With Portal Vein Tumor Thrombosis",[90],"2018-04-15","2019-12-15","2016-12-15",54,[1202],"Portal Vein Tumor Thrombus",[1181],{"trials":1205,"activeCount":99},[],{"intervention":1207,"totalTrials":117,"cells":1208},"candesartan cilexetil",{"EARLY_PHASE1":1209,"PHASE1":1211,"PHASE2":1213,"PHASE3":1215,"PHASE4":1217,"NA":1228},{"trials":1210,"activeCount":99},[],{"trials":1212,"activeCount":99},[],{"trials":1214,"activeCount":99},[],{"trials":1216,"activeCount":99},[],{"trials":1218,"activeCount":99},[1219],{"nctId":1220,"briefTitle":1221,"status":425,"phases":1222,"completion":1223,"enrollment":1224,"conditions":1225,"interventions":1227},"NCT00360763","Study of Optimal Treatment Plan in Hypertensives With Anti-AT1-Receptor Autoantibody",[90],"2006-12",600,[1226],"Hypertension",[1207],{"trials":1229,"activeCount":99},[],{"intervention":1231,"totalTrials":117,"cells":1232},"Pioglitazone and Metformin",{"EARLY_PHASE1":1233,"PHASE1":1235,"PHASE2":1237,"PHASE3":1239,"PHASE4":1241,"NA":1251},{"trials":1234,"activeCount":99},[],{"trials":1236,"activeCount":99},[],{"trials":1238,"activeCount":99},[],{"trials":1240,"activeCount":99},[],{"trials":1242,"activeCount":99},[1243],{"nctId":1244,"briefTitle":1245,"status":436,"phases":1246,"primaryCompletion":899,"completion":899,"start":1247,"enrollment":1248,"conditions":1249,"interventions":1250},"NCT02099838","Effectiveness and Safety of Adding Compound Preparation of Pioglitazone and Metformin for Type 2 Diabetic Patients",[90],"2012-01",98,[718],[1231],{"trials":1252,"activeCount":99},[],{"intervention":1254,"totalTrials":117,"cells":1255},"Hetrombopag Olamine",{"EARLY_PHASE1":1256,"PHASE1":1258,"PHASE2":1260,"PHASE3":1262,"PHASE4":1264,"NA":1277},{"trials":1257,"activeCount":99},[],{"trials":1259,"activeCount":99},[],{"trials":1261,"activeCount":99},[],{"trials":1263,"activeCount":99},[],{"trials":1265,"activeCount":99},[1266],{"nctId":1267,"briefTitle":1268,"status":425,"phases":1269,"primaryCompletion":1270,"completion":1271,"start":1272,"enrollment":527,"conditions":1273,"interventions":1276},"NCT05575986","Herombopag Olamine in the Treatment of Thrombocytopenia After Chemotherapy",[90],"2023-10","2023-12","2022-10",[1274,1275],"Malignant Tumors of the Digestive System","Trombocitopenia",[1254],{"trials":1278,"activeCount":99},[],{"intervention":1280,"totalTrials":117,"cells":1281},"Qiliqiangxin",{"EARLY_PHASE1":1282,"PHASE1":1284,"PHASE2":1286,"PHASE3":1288,"PHASE4":1290,"NA":1303},{"trials":1283,"activeCount":99},[],{"trials":1285,"activeCount":99},[],{"trials":1287,"activeCount":99},[],{"trials":1289,"activeCount":99},[],{"trials":1291,"activeCount":99},[1292],{"nctId":1293,"briefTitle":1294,"status":436,"phases":1295,"primaryCompletion":1296,"completion":1297,"start":1247,"enrollment":1298,"conditions":1299,"interventions":1302},"NCT01293903","Study of Qiliqiangxin Capsule to Treat Dilated Cardiomyopathy",[90],"2015-12-31","2016-09-30",374,[1300,1301],"Dilated Cardiomyopathy","Heart Failure",[1280],{"trials":1304,"activeCount":99},[],{"intervention":1306,"totalTrials":117,"cells":1307},"cognitive function",{"EARLY_PHASE1":1308,"PHASE1":1310,"PHASE2":1312,"PHASE3":1314,"PHASE4":1316,"NA":1328},{"trials":1309,"activeCount":99},[],{"trials":1311,"activeCount":99},[],{"trials":1313,"activeCount":99},[],{"trials":1315,"activeCount":99},[],{"trials":1317,"activeCount":99},[1318],{"nctId":1319,"briefTitle":1320,"status":425,"phases":1321,"completion":1322,"start":1323,"enrollment":1324,"conditions":1325,"interventions":1327},"NCT00297245","Gastrodin Prevents Cognitive Decline Related to Cardiopulmonary Bypass",[90],"2006-05","2006-02",200,[1326],"Cognitive Decline",[1306],{"trials":1329,"activeCount":99},[],{"intervention":916,"totalTrials":117,"cells":1331},{"EARLY_PHASE1":1332,"PHASE1":1334,"PHASE2":1336,"PHASE3":1338,"PHASE4":1340,"NA":1346},{"trials":1333,"activeCount":99},[],{"trials":1335,"activeCount":99},[],{"trials":1337,"activeCount":99},[],{"trials":1339,"activeCount":99},[],{"trials":1341,"activeCount":99},[1342],{"nctId":907,"briefTitle":908,"status":436,"phases":1343,"primaryCompletion":910,"completion":910,"start":911,"enrollment":750,"conditions":1344,"interventions":1345},[90],[913,914],[916,866,917],{"trials":1347,"activeCount":99},[],{"intervention":917,"totalTrials":117,"cells":1349},{"EARLY_PHASE1":1350,"PHASE1":1352,"PHASE2":1354,"PHASE3":1356,"PHASE4":1358,"NA":1364},{"trials":1351,"activeCount":99},[],{"trials":1353,"activeCount":99},[],{"trials":1355,"activeCount":99},[],{"trials":1357,"activeCount":99},[],{"trials":1359,"activeCount":99},[1360],{"nctId":907,"briefTitle":908,"status":436,"phases":1361,"primaryCompletion":910,"completion":910,"start":911,"enrollment":750,"conditions":1362,"interventions":1363},[90],[913,914],[916,866,917],{"trials":1365,"activeCount":99},[],{"intervention":1367,"totalTrials":117,"cells":1368},"glargine + exenatide",{"EARLY_PHASE1":1369,"PHASE1":1371,"PHASE2":1373,"PHASE3":1375,"PHASE4":1377,"NA":1390},{"trials":1370,"activeCount":99},[],{"trials":1372,"activeCount":99},[],{"trials":1374,"activeCount":99},[],{"trials":1376,"activeCount":99},[],{"trials":1378,"activeCount":99},[1379],{"nctId":1380,"briefTitle":1381,"status":436,"phases":1382,"primaryCompletion":1383,"completion":1383,"start":1384,"enrollment":1385,"conditions":1386,"interventions":1388},"NCT02467920","Efficacy and Safety of Basal Insulin Glargine Combination With Exenatide Bid vs Aspart30 in T2DM",[90],"2017-12","2015-08",349,[1387],"Type 2 Diabetes Mellitus",[1367,1389],"aspart 30",{"trials":1391,"activeCount":99},[],{"intervention":1389,"totalTrials":117,"cells":1393},{"EARLY_PHASE1":1394,"PHASE1":1396,"PHASE2":1398,"PHASE3":1400,"PHASE4":1402,"NA":1408},{"trials":1395,"activeCount":99},[],{"trials":1397,"activeCount":99},[],{"trials":1399,"activeCount":99},[],{"trials":1401,"activeCount":99},[],{"trials":1403,"activeCount":99},[1404],{"nctId":1380,"briefTitle":1381,"status":436,"phases":1405,"primaryCompletion":1383,"completion":1383,"start":1384,"enrollment":1385,"conditions":1406,"interventions":1407},[90],[1387],[1367,1389],{"trials":1409,"activeCount":99},[],{"intervention":973,"totalTrials":117,"cells":1411},{"EARLY_PHASE1":1412,"PHASE1":1414,"PHASE2":1416,"PHASE3":1418,"PHASE4":1420,"NA":1426},{"trials":1413,"activeCount":99},[],{"trials":1415,"activeCount":99},[],{"trials":1417,"activeCount":99},[],{"trials":1419,"activeCount":99},[],{"trials":1421,"activeCount":99},[1422],{"nctId":963,"briefTitle":964,"status":425,"phases":1423,"primaryCompletion":966,"completion":967,"start":968,"enrollment":112,"conditions":1424,"interventions":1425},[90],[970,971],[973,890,974],{"trials":1427,"activeCount":99},[],{"intervention":929,"totalTrials":117,"cells":1429},{"EARLY_PHASE1":1430,"PHASE1":1432,"PHASE2":1434,"PHASE3":1436,"PHASE4":1438,"NA":1444},{"trials":1431,"activeCount":99},[],{"trials":1433,"activeCount":99},[],{"trials":1435,"activeCount":99},[],{"trials":1437,"activeCount":99},[],{"trials":1439,"activeCount":99},[1440],{"nctId":919,"briefTitle":920,"status":436,"phases":1441,"primaryCompletion":922,"completion":923,"start":924,"enrollment":925,"conditions":1442,"interventions":1443},[90],[927,902],[929,866],{"trials":1445,"activeCount":99},[],{"intervention":560,"totalTrials":95,"cells":1447},{"EARLY_PHASE1":1448,"PHASE1":1450,"PHASE2":1452,"PHASE3":1458,"PHASE4":1471,"NA":1473},{"trials":1449,"activeCount":99},[],{"trials":1451,"activeCount":99},[],{"trials":1453,"activeCount":99},[1454],{"nctId":548,"briefTitle":549,"status":425,"phases":1455,"primaryCompletion":551,"completion":552,"start":553,"enrollment":11,"conditions":1456,"interventions":1457},[88],[555],[44,557,558,559,560],{"trials":1459,"activeCount":99},[1460],{"nctId":1461,"briefTitle":1462,"status":425,"phases":1463,"primaryCompletion":1464,"completion":1465,"start":1466,"enrollment":1467,"conditions":1468,"interventions":1469},"NCT03598348","Evaluate the Efficacy of Maintenance Treatment With Capecitabine Plus Apatinib in Advanced Gastric Cancer",[89],"2020-01-16","2020-10-16","2018-01-16",288,[18],[1470,560],"Apatinib+Capecitabine",{"trials":1472,"activeCount":99},[],{"trials":1474,"activeCount":99},[],{"intervention":1476,"totalTrials":95,"cells":1477},"ADV-Tk",{"EARLY_PHASE1":1478,"PHASE1":1480,"PHASE2":1482,"PHASE3":1496,"PHASE4":1507,"NA":1509},{"trials":1479,"activeCount":99},[],{"trials":1481,"activeCount":99},[],{"trials":1483,"activeCount":99},[1484],{"nctId":1485,"briefTitle":1486,"status":436,"phases":1487,"primaryCompletion":1488,"completion":1489,"start":1490,"enrollment":1491,"conditions":1492,"interventions":1493},"NCT02202564","Preliminary Results for the Double-dose Adenovirus-mediated Adjuvant Therapy Improving Outcome of Liver Transplantation in Patients With Advanced Hepatocellular Carcinoma",[88],"2011-10","2013-08","2006-10",81,[1102,33],[1494,1495],"ADV-TK","ganciclovir",{"trials":1497,"activeCount":99},[1498],{"nctId":1499,"briefTitle":1500,"status":425,"phases":1501,"primaryCompletion":1502,"completion":1502,"start":1503,"enrollment":1504,"conditions":1505,"interventions":1506},"NCT03313596","Multicenter RCT of ADV-TK Gene Therapy Improving the Outcome of Liver Transplantation for Advanced HCC",[89],"2019-12","2013-03",180,[33],[1476],{"trials":1508,"activeCount":99},[],{"trials":1510,"activeCount":99},[],{"intervention":1512,"totalTrials":117,"cells":1513},"Albumin-bound Paclitaxel plus S-1",{"EARLY_PHASE1":1514,"PHASE1":1516,"PHASE2":1518,"PHASE3":1520,"PHASE4":1533,"NA":1535},{"trials":1515,"activeCount":99},[],{"trials":1517,"activeCount":99},[],{"trials":1519,"activeCount":99},[],{"trials":1521,"activeCount":99},[1522],{"nctId":1523,"briefTitle":1524,"status":425,"phases":1525,"primaryCompletion":1526,"completion":1527,"start":1528,"enrollment":1529,"conditions":1530,"interventions":1531},"NCT03801668","Albumin-bound Paclitaxel Plus S-1 Versus SOX as First-line Treatment in Advanced or Recurrent Gastric Adenocarcinoma",[89],"2022-12-31","2023-03-31","2019-03-08",294,[18],[1512,1532],"Oxaliplatin plus S-1",{"trials":1534,"activeCount":99},[],{"trials":1536,"activeCount":99},[],{"intervention":1532,"totalTrials":117,"cells":1538},{"EARLY_PHASE1":1539,"PHASE1":1541,"PHASE2":1543,"PHASE3":1545,"PHASE4":1551,"NA":1553},{"trials":1540,"activeCount":99},[],{"trials":1542,"activeCount":99},[],{"trials":1544,"activeCount":99},[],{"trials":1546,"activeCount":99},[1547],{"nctId":1523,"briefTitle":1524,"status":425,"phases":1548,"primaryCompletion":1526,"completion":1527,"start":1528,"enrollment":1529,"conditions":1549,"interventions":1550},[89],[18],[1512,1532],{"trials":1552,"activeCount":99},[],{"trials":1554,"activeCount":99},[],{"intervention":1556,"totalTrials":117,"cells":1557},"Chemotherapy",{"EARLY_PHASE1":1558,"PHASE1":1560,"PHASE2":1562,"PHASE3":1564,"PHASE4":1576,"NA":1578},{"trials":1559,"activeCount":99},[],{"trials":1561,"activeCount":99},[],{"trials":1563,"activeCount":99},[],{"trials":1565,"activeCount":99},[1566],{"nctId":1567,"briefTitle":1568,"status":425,"phases":1569,"primaryCompletion":1570,"completion":1571,"start":1572,"enrollment":1573,"conditions":1574,"interventions":1575},"NCT03601988","Phase III Trial of Adjuvant Chemo-radiotherapy After D2 Surgery of Gastric Cancer",[89],"2020-07-28","2022-07-28","2018-07-28",408,[18],[1556],{"trials":1577,"activeCount":99},[],{"trials":1579,"activeCount":99},[],{"intervention":476,"totalTrials":117,"cells":1581},{"EARLY_PHASE1":1582,"PHASE1":1584,"PHASE2":1586,"PHASE3":1588,"PHASE4":1594,"NA":1596},{"trials":1583,"activeCount":99},[],{"trials":1585,"activeCount":99},[],{"trials":1587,"activeCount":99},[],{"trials":1589,"activeCount":99},[1590],{"nctId":468,"briefTitle":469,"status":436,"phases":1591,"primaryCompletion":471,"completion":471,"start":472,"enrollment":473,"conditions":1592,"interventions":1593},[89],[27,15,21],[476,457],{"trials":1595,"activeCount":99},[],{"trials":1597,"activeCount":99},[],{"intervention":1599,"totalTrials":117,"cells":1600},"cyclophosphamide",{"EARLY_PHASE1":1601,"PHASE1":1603,"PHASE2":1605,"PHASE3":1607,"PHASE4":1620,"NA":1622},{"trials":1602,"activeCount":99},[],{"trials":1604,"activeCount":99},[],{"trials":1606,"activeCount":99},[],{"trials":1608,"activeCount":99},[1609],{"nctId":1610,"briefTitle":1611,"status":436,"phases":1612,"primaryCompletion":1613,"completion":1614,"start":1615,"enrollment":1616,"conditions":1617,"interventions":1619},"NCT00999986","Low Dose Cyclophosphamide Treats Genital Warts",[89],"2009-06","2009-08","2007-01",104,[1618],"Genital Wart",[1599],{"trials":1621,"activeCount":99},[],{"trials":1623,"activeCount":99},[],{"intervention":1625,"totalTrials":117,"cells":1626},"gemcitabine",{"EARLY_PHASE1":1627,"PHASE1":1629,"PHASE2":1631,"PHASE3":1633,"PHASE4":1646,"NA":1648},{"trials":1628,"activeCount":99},[],{"trials":1630,"activeCount":99},[],{"trials":1632,"activeCount":99},[],{"trials":1634,"activeCount":99},[1635],{"nctId":1636,"briefTitle":1637,"status":436,"phases":1638,"primaryCompletion":1639,"completion":1640,"start":1641,"enrollment":1642,"conditions":1643,"interventions":1645},"NCT00644618","Randomized Controlled Trial of Gemcitabine Combined With 125I Brachytherapy",[89],"2007-12","2008-01","2003-01",120,[1644],"Locally Advanced Pancreatic Cancer",[1625],{"trials":1647,"activeCount":99},[],{"trials":1649,"activeCount":99},[],{"intervention":1470,"totalTrials":117,"cells":1651},{"EARLY_PHASE1":1652,"PHASE1":1654,"PHASE2":1656,"PHASE3":1658,"PHASE4":1664,"NA":1666},{"trials":1653,"activeCount":99},[],{"trials":1655,"activeCount":99},[],{"trials":1657,"activeCount":99},[],{"trials":1659,"activeCount":99},[1660],{"nctId":1461,"briefTitle":1462,"status":425,"phases":1661,"primaryCompletion":1464,"completion":1465,"start":1466,"enrollment":1467,"conditions":1662,"interventions":1663},[89],[18],[1470,560],{"trials":1665,"activeCount":99},[],{"trials":1667,"activeCount":99},[],{"intervention":1669,"totalTrials":117,"cells":1670},"rAAV2-ND4",{"EARLY_PHASE1":1671,"PHASE1":1673,"PHASE2":1675,"PHASE3":1677,"PHASE4":1690,"NA":1692},{"trials":1672,"activeCount":99},[],{"trials":1674,"activeCount":99},[],{"trials":1676,"activeCount":99},[],{"trials":1678,"activeCount":99},[1679],{"nctId":1680,"briefTitle":1681,"status":425,"phases":1682,"primaryCompletion":1683,"completion":1684,"start":1685,"enrollment":1686,"conditions":1687,"interventions":1689},"NCT03153293","A Single Intravitreal Injection of rAAV2-ND4 for the Treatment of Leber's Hereditary Optic Neuropathy",[88,89],"2020-01-15","2025-01-15","2017-12-27",159,[1688],"Leber Hereditary Optic Neuropathy",[1669],{"trials":1691,"activeCount":99},[],{"trials":1693,"activeCount":99},[],{"intervention":1695,"totalTrials":117,"cells":1696},"s-LMWH",{"EARLY_PHASE1":1697,"PHASE1":1699,"PHASE2":1701,"PHASE3":1703,"PHASE4":1719,"NA":1721},{"trials":1698,"activeCount":99},[],{"trials":1700,"activeCount":99},[],{"trials":1702,"activeCount":99},[],{"trials":1704,"activeCount":99},[1705],{"nctId":1706,"briefTitle":1707,"status":436,"phases":1708,"primaryCompletion":1709,"completion":429,"start":1710,"enrollment":1711,"conditions":1712,"interventions":1717},"NCT02935530","Thromboprophylaxis After Surgery for Gynecologic Malignancy in China",[89],"2017-08","2016-01",315,[1713,1714,1715,1716],"Gynecologic Neoplasms","Venous Thromboembolism","Low Molecular Weight Heparin","Argatroban",[1695,1718,1716],"LMWH",{"trials":1720,"activeCount":99},[],{"trials":1722,"activeCount":99},[],{"intervention":1718,"totalTrials":117,"cells":1724},{"EARLY_PHASE1":1725,"PHASE1":1727,"PHASE2":1729,"PHASE3":1731,"PHASE4":1737,"NA":1739},{"trials":1726,"activeCount":99},[],{"trials":1728,"activeCount":99},[],{"trials":1730,"activeCount":99},[],{"trials":1732,"activeCount":99},[1733],{"nctId":1706,"briefTitle":1707,"status":436,"phases":1734,"primaryCompletion":1709,"completion":429,"start":1710,"enrollment":1711,"conditions":1735,"interventions":1736},[89],[1713,1714,1715,1716],[1695,1718,1716],{"trials":1738,"activeCount":99},[],{"trials":1740,"activeCount":99},[],{"intervention":1716,"totalTrials":117,"cells":1742},{"EARLY_PHASE1":1743,"PHASE1":1745,"PHASE2":1747,"PHASE3":1749,"PHASE4":1755,"NA":1757},{"trials":1744,"activeCount":99},[],{"trials":1746,"activeCount":99},[],{"trials":1748,"activeCount":99},[],{"trials":1750,"activeCount":99},[1751],{"nctId":1706,"briefTitle":1707,"status":436,"phases":1752,"primaryCompletion":1709,"completion":429,"start":1710,"enrollment":1711,"conditions":1753,"interventions":1754},[89],[1713,1714,1715,1716],[1695,1718,1716],{"trials":1756,"activeCount":99},[],{"trials":1758,"activeCount":99},[],{"intervention":1760,"totalTrials":117,"cells":1761},"ADV-TK\u002FGCV",{"EARLY_PHASE1":1762,"PHASE1":1764,"PHASE2":1766,"PHASE3":1780,"PHASE4":1782,"NA":1784},{"trials":1763,"activeCount":99},[],{"trials":1765,"activeCount":99},[],{"trials":1767,"activeCount":99},[1768],{"nctId":1769,"briefTitle":1770,"status":436,"phases":1771,"primaryCompletion":1772,"completion":1773,"start":1640,"enrollment":1774,"conditions":1775,"interventions":1778},"NCT00870181","ADV-TK Improves Outcome of Recurrent High-Grade Glioma",[88],"2011-12","2012-12",47,[1776,1777],"Malignant Glioma of Brain","Glioblastoma",[1760,1779],"systemic chemotherapy",{"trials":1781,"activeCount":99},[],{"trials":1783,"activeCount":99},[],{"trials":1785,"activeCount":99},[],{"intervention":1779,"totalTrials":117,"cells":1787},{"EARLY_PHASE1":1788,"PHASE1":1790,"PHASE2":1792,"PHASE3":1798,"PHASE4":1800,"NA":1802},{"trials":1789,"activeCount":99},[],{"trials":1791,"activeCount":99},[],{"trials":1793,"activeCount":99},[1794],{"nctId":1769,"briefTitle":1770,"status":436,"phases":1795,"primaryCompletion":1772,"completion":1773,"start":1640,"enrollment":1774,"conditions":1796,"interventions":1797},[88],[1776,1777],[1760,1779],{"trials":1799,"activeCount":99},[],{"trials":1801,"activeCount":99},[],{"trials":1803,"activeCount":99},[],{"intervention":1805,"totalTrials":117,"cells":1806},"chemotherapy alone following radical resection",{"EARLY_PHASE1":1807,"PHASE1":1809,"PHASE2":1811,"PHASE3":1821,"PHASE4":1823,"NA":1825},{"trials":1808,"activeCount":99},[],{"trials":1810,"activeCount":99},[],{"trials":1812,"activeCount":99},[1813],{"nctId":1814,"briefTitle":1815,"status":425,"phases":1816,"primaryCompletion":1017,"completion":1817,"start":1818,"enrollment":527,"conditions":1819,"interventions":1820},"NCT01197118","Postoperative Sequence Chemoradiotherapy Compared With Chemotherapy Alone for Advanced Gastric Cancer",[88],"2011-05","2010-09",[18],[1805],{"trials":1822,"activeCount":99},[],{"trials":1824,"activeCount":99},[],{"trials":1826,"activeCount":99},[],{"intervention":557,"totalTrials":117,"cells":1828},{"EARLY_PHASE1":1829,"PHASE1":1831,"PHASE2":1833,"PHASE3":1839,"PHASE4":1841,"NA":1843},{"trials":1830,"activeCount":99},[],{"trials":1832,"activeCount":99},[],{"trials":1834,"activeCount":99},[1835],{"nctId":548,"briefTitle":549,"status":425,"phases":1836,"primaryCompletion":551,"completion":552,"start":553,"enrollment":11,"conditions":1837,"interventions":1838},[88],[555],[44,557,558,559,560],{"trials":1840,"activeCount":99},[],{"trials":1842,"activeCount":99},[],{"trials":1844,"activeCount":99},[],{"intervention":558,"totalTrials":117,"cells":1846},{"EARLY_PHASE1":1847,"PHASE1":1849,"PHASE2":1851,"PHASE3":1857,"PHASE4":1859,"NA":1861},{"trials":1848,"activeCount":99},[],{"trials":1850,"activeCount":99},[],{"trials":1852,"activeCount":99},[1853],{"nctId":548,"briefTitle":549,"status":425,"phases":1854,"primaryCompletion":551,"completion":552,"start":553,"enrollment":11,"conditions":1855,"interventions":1856},[88],[555],[44,557,558,559,560],{"trials":1858,"activeCount":99},[],{"trials":1860,"activeCount":99},[],{"trials":1862,"activeCount":99},[],{"intervention":1864,"totalTrials":117,"cells":1865},"Albumin-bound Paclitaxel Plus SHR-1210",{"EARLY_PHASE1":1866,"PHASE1":1868,"PHASE2":1870,"PHASE3":1883,"PHASE4":1885,"NA":1887},{"trials":1867,"activeCount":99},[],{"trials":1869,"activeCount":99},[],{"trials":1871,"activeCount":99},[1872],{"nctId":1873,"briefTitle":1874,"status":1875,"phases":1876,"primaryCompletion":1877,"completion":1877,"start":1878,"enrollment":8,"conditions":1879,"interventions":1881},"NCT04294784","Nab-paclitaxel Plus PD-1 Inhibitor Versus Nab-paclitaxel As Second-line Treatment in Advanced Gastric Cancer","TERMINATED",[88],"2023-11-30","2020-04-03",[18,1880],"GastroEsophageal Cancer",[1864,1882],"Albumin-bound Paclitaxel",{"trials":1884,"activeCount":99},[],{"trials":1886,"activeCount":99},[],{"trials":1888,"activeCount":99},[],{"intervention":1882,"totalTrials":117,"cells":1890},{"EARLY_PHASE1":1891,"PHASE1":1893,"PHASE2":1895,"PHASE3":1901,"PHASE4":1903,"NA":1905},{"trials":1892,"activeCount":99},[],{"trials":1894,"activeCount":99},[],{"trials":1896,"activeCount":99},[1897],{"nctId":1873,"briefTitle":1874,"status":1875,"phases":1898,"primaryCompletion":1877,"completion":1877,"start":1878,"enrollment":8,"conditions":1899,"interventions":1900},[88],[18,1880],[1864,1882],{"trials":1902,"activeCount":99},[],{"trials":1904,"activeCount":99},[],{"trials":1906,"activeCount":99},[],{"intervention":1908,"totalTrials":117,"cells":1909},"Terepril monoclonal antibody; Apatinib",{"EARLY_PHASE1":1910,"PHASE1":1912,"PHASE2":1914,"PHASE3":1926,"PHASE4":1928,"NA":1930},{"trials":1911,"activeCount":99},[],{"trials":1913,"activeCount":99},[],{"trials":1915,"activeCount":99},[1916],{"nctId":1917,"briefTitle":1918,"status":425,"phases":1919,"primaryCompletion":1920,"completion":1921,"start":1502,"enrollment":1922,"conditions":1923,"interventions":1925},"NCT04165174","PD-1 Monoclonal Antibody Plus Apatinib Combined With SBRT in HCC With PVTT",[88],"2020-11","2020-12",20,[1924],"HCC",[1908],{"trials":1927,"activeCount":99},[],{"trials":1929,"activeCount":99},[],{"trials":1931,"activeCount":99},[],{"intervention":1933,"totalTrials":117,"cells":1934},"Paclitaxel for",{"EARLY_PHASE1":1935,"PHASE1":1937,"PHASE2":1939,"PHASE3":1951,"PHASE4":1953,"NA":1955},{"trials":1936,"activeCount":99},[],{"trials":1938,"activeCount":99},[],{"trials":1940,"activeCount":99},[1941],{"nctId":1942,"briefTitle":1943,"status":425,"phases":1944,"primaryCompletion":1945,"completion":552,"start":1946,"enrollment":1947,"conditions":1948,"interventions":1950},"NCT03818282","Efficacy and Safety of Paclitaxel for Injection (Albumin-bound) for First-line Chemotherapy of Ovarian Cancer",[88],"2023-06-30","2019-03-01",77,[1949],"Ovarian Cancer",[1933],{"trials":1952,"activeCount":99},[],{"trials":1954,"activeCount":99},[],{"trials":1956,"activeCount":99},[],{"intervention":1958,"totalTrials":117,"cells":1959},"Tislelizumab plus Fruquintinib and SBRT",{"EARLY_PHASE1":1960,"PHASE1":1962,"PHASE2":1964,"PHASE3":1977,"PHASE4":1979,"NA":1981},{"trials":1961,"activeCount":99},[],{"trials":1963,"activeCount":99},[],{"trials":1965,"activeCount":99},[1966],{"nctId":1967,"briefTitle":1968,"status":425,"phases":1969,"primaryCompletion":1970,"completion":1971,"start":1972,"enrollment":1973,"conditions":1974,"interventions":1976},"NCT04924179","Tislelizumab Combined With Fruquintinib and SBRT as Athird-line and Posterior Line Treatment in Patients With Advanced CRC",[88],"2022-12","2024-06","2021-06-01",25,[1975],"Patients With Advanced Metastatic Colorectal Cancer",[1958],{"trials":1978,"activeCount":99},[],{"trials":1980,"activeCount":99},[],{"trials":1982,"activeCount":99},[],{"intervention":572,"totalTrials":117,"cells":1984},{"EARLY_PHASE1":1985,"PHASE1":1987,"PHASE2":1989,"PHASE3":1995,"PHASE4":1997,"NA":1999},{"trials":1986,"activeCount":99},[],{"trials":1988,"activeCount":99},[],{"trials":1990,"activeCount":99},[1991],{"nctId":562,"briefTitle":563,"status":425,"phases":1992,"primaryCompletion":565,"completion":566,"start":567,"enrollment":11,"conditions":1993,"interventions":1994},[88],[569,570],[572,44],{"trials":1996,"activeCount":99},[],{"trials":1998,"activeCount":99},[],{"trials":2000,"activeCount":99},[],{"intervention":1495,"totalTrials":117,"cells":2002},{"EARLY_PHASE1":2003,"PHASE1":2005,"PHASE2":2007,"PHASE3":2013,"PHASE4":2015,"NA":2017},{"trials":2004,"activeCount":99},[],{"trials":2006,"activeCount":99},[],{"trials":2008,"activeCount":99},[2009],{"nctId":1485,"briefTitle":1486,"status":436,"phases":2010,"primaryCompletion":1488,"completion":1489,"start":1490,"enrollment":1491,"conditions":2011,"interventions":2012},[88],[1102,33],[1494,1495],{"trials":2014,"activeCount":99},[],{"trials":2016,"activeCount":99},[],{"trials":2018,"activeCount":99},[],{"intervention":2020,"totalTrials":117,"cells":2021},"SBRT Sequential CapeOX Regimen Combined With Bevacizumab and Sintilimab",{"EARLY_PHASE1":2022,"PHASE1":2024,"PHASE2":2026,"PHASE3":2038,"PHASE4":2040,"NA":2042},{"trials":2023,"activeCount":99},[],{"trials":2025,"activeCount":99},[],{"trials":2027,"activeCount":99},[2028],{"nctId":2029,"briefTitle":2030,"status":425,"phases":2031,"primaryCompletion":2032,"completion":2033,"start":2034,"enrollment":11,"conditions":2035,"interventions":2037},"NCT05438108","SBRT Sequential CapeOX Regimen Combined With Bevacizumab and Sintilimab in First-line Treatment of mCRC",[88],"2023-01-31","2024-01-31","2022-07-01",[2036],"Metastatic Colorectal Cancer",[2020],{"trials":2039,"activeCount":99},[],{"trials":2041,"activeCount":99},[],{"trials":2043,"activeCount":99},[],{"intervention":2045,"totalTrials":117,"cells":2046},"Nab-paclitaxel + Cisplatin",{"EARLY_PHASE1":2047,"PHASE1":2049,"PHASE2":2051,"PHASE3":2064,"PHASE4":2066,"NA":2068},{"trials":2048,"activeCount":99},[],{"trials":2050,"activeCount":99},[],{"trials":2052,"activeCount":99},[2053],{"nctId":2054,"briefTitle":2055,"status":425,"phases":2056,"primaryCompletion":2057,"completion":2058,"start":2059,"enrollment":884,"conditions":2060,"interventions":2062},"NCT04692051","A Phase II Study for Nab-paclitaxel Plus Cisplatin vs Gemcitabine Plus Cispatin as First Line Chemotherapy in Advanced Biliary Tract Cancer",[88],"2021-03-01","2021-09-01","2019-09-01",[2061],"Biliary Tract Cancer",[2045,2063],"Gemcitabine + Cisplatin",{"trials":2065,"activeCount":99},[],{"trials":2067,"activeCount":99},[],{"trials":2069,"activeCount":99},[],{"intervention":2063,"totalTrials":117,"cells":2071},{"EARLY_PHASE1":2072,"PHASE1":2074,"PHASE2":2076,"PHASE3":2082,"PHASE4":2084,"NA":2086},{"trials":2073,"activeCount":99},[],{"trials":2075,"activeCount":99},[],{"trials":2077,"activeCount":99},[2078],{"nctId":2054,"briefTitle":2055,"status":425,"phases":2079,"primaryCompletion":2057,"completion":2058,"start":2059,"enrollment":884,"conditions":2080,"interventions":2081},[88],[2061],[2045,2063],{"trials":2083,"activeCount":99},[],{"trials":2085,"activeCount":99},[],{"trials":2087,"activeCount":99},[],{"intervention":2089,"totalTrials":539,"cells":2090},"ICG",{"EARLY_PHASE1":2091,"PHASE1":2093,"PHASE2":2126,"PHASE3":2128,"PHASE4":2130,"NA":2132},{"trials":2092,"activeCount":99},[],{"trials":2094,"activeCount":99},[2095,2105,2116],{"nctId":2096,"briefTitle":2097,"status":425,"phases":2098,"primaryCompletion":2099,"completion":2100,"start":2101,"enrollment":527,"conditions":2102,"interventions":2103},"NCT03320772","TMVP1-ICG Mapping in Laparoscopic SLN Detection in Cervical Cancer",[87],"2018-05","2019-05","2017-05-01",[15],[2104,2089],"TMVP1-ICG",{"nctId":2106,"briefTitle":2107,"status":425,"phases":2108,"primaryCompletion":2109,"completion":2110,"start":2111,"enrollment":527,"conditions":2112,"interventions":2114},"NCT03321461","TMTP1-ICG Mapping in Colposcopy-directed Biopsy",[87],"2020-08-31","2021-12","2017-11-01",[2113],"Cervical Intraepithelial Neoplasia",[2115,2089],"TMTP1",{"nctId":2117,"briefTitle":2118,"status":425,"phases":2119,"primaryCompletion":2120,"completion":2121,"start":2122,"enrollment":527,"conditions":2123,"interventions":2124},"NCT03321448","TMTP1-ICG Mapping in Laparoscopic SLN Detection in Cervical Cancer",[87],"2018-09","2019-09","2017-09-01",[15],[2125,2089],"TMTP1-ICG",{"trials":2127,"activeCount":99},[],{"trials":2129,"activeCount":99},[],{"trials":2131,"activeCount":99},[],{"trials":2133,"activeCount":99},[],{"intervention":2104,"totalTrials":117,"cells":2135},{"EARLY_PHASE1":2136,"PHASE1":2138,"PHASE2":2144,"PHASE3":2146,"PHASE4":2148,"NA":2150},{"trials":2137,"activeCount":99},[],{"trials":2139,"activeCount":99},[2140],{"nctId":2096,"briefTitle":2097,"status":425,"phases":2141,"primaryCompletion":2099,"completion":2100,"start":2101,"enrollment":527,"conditions":2142,"interventions":2143},[87],[15],[2104,2089],{"trials":2145,"activeCount":99},[],{"trials":2147,"activeCount":99},[],{"trials":2149,"activeCount":99},[],{"trials":2151,"activeCount":99},[],{"intervention":2153,"totalTrials":117,"cells":2154},"mosapride",{"EARLY_PHASE1":2155,"PHASE1":2157,"PHASE2":2169,"PHASE3":2171,"PHASE4":2173,"NA":2175},{"trials":2156,"activeCount":99},[],{"trials":2158,"activeCount":99},[2159],{"nctId":2160,"briefTitle":2161,"status":425,"phases":2162,"primaryCompletion":2163,"completion":2163,"start":2164,"enrollment":2165,"conditions":2166,"interventions":2168},"NCT01781897","Electroacupuncture for the Treatment of Functional Constipation",[87],"2015-12","2013-02",243,[2167],"Functional Constipation",[2153],{"trials":2170,"activeCount":99},[],{"trials":2172,"activeCount":99},[],{"trials":2174,"activeCount":99},[],{"trials":2176,"activeCount":99},[],{"intervention":2178,"totalTrials":117,"cells":2179},"T512",{"EARLY_PHASE1":2180,"PHASE1":2182,"PHASE2":2194,"PHASE3":2196,"PHASE4":2198,"NA":2200},{"trials":2181,"activeCount":99},[],{"trials":2183,"activeCount":99},[2184],{"nctId":2185,"briefTitle":2186,"status":425,"phases":2187,"primaryCompletion":2188,"completion":2189,"start":2190,"enrollment":527,"conditions":2191,"interventions":2193},"NCT03226470","Study of Targeted Therapy Using Transcription Activator-like Effector Nucleases in Cervical Precancerous Lesions",[87],"2022-02-10","2022-06-10","2017-03-10",[2192],"Human Papillomavirus-Related Malignant Neoplasm",[2178],{"trials":2195,"activeCount":99},[],{"trials":2197,"activeCount":99},[],{"trials":2199,"activeCount":99},[],{"trials":2201,"activeCount":99},[],{"intervention":2203,"totalTrials":117,"cells":2204},"Mosapride Citrate",{"EARLY_PHASE1":2205,"PHASE1":2207,"PHASE2":2217,"PHASE3":2219,"PHASE4":2221,"NA":2223},{"trials":2206,"activeCount":99},[],{"trials":2208,"activeCount":99},[2209],{"nctId":2210,"briefTitle":2211,"status":425,"phases":2212,"primaryCompletion":2163,"completion":2163,"start":1016,"enrollment":2213,"conditions":2214,"interventions":2216},"NCT01274793","Trial for Quantity-Effect Relationship of Acupuncture With Two-ways Regulation to Treat Functional Enteropathy",[87],240,[2167,2215],"Functional Diarrhea",[2203],{"trials":2218,"activeCount":99},[],{"trials":2220,"activeCount":99},[],{"trials":2222,"activeCount":99},[],{"trials":2224,"activeCount":99},[],{"intervention":2115,"totalTrials":117,"cells":2226},{"EARLY_PHASE1":2227,"PHASE1":2229,"PHASE2":2235,"PHASE3":2237,"PHASE4":2239,"NA":2241},{"trials":2228,"activeCount":99},[],{"trials":2230,"activeCount":99},[2231],{"nctId":2106,"briefTitle":2107,"status":425,"phases":2232,"primaryCompletion":2109,"completion":2110,"start":2111,"enrollment":527,"conditions":2233,"interventions":2234},[87],[2113],[2115,2089],{"trials":2236,"activeCount":99},[],{"trials":2238,"activeCount":99},[],{"trials":2240,"activeCount":99},[],{"trials":2242,"activeCount":99},[],{"intervention":2244,"totalTrials":117,"cells":2245},"ZFN-603 and ZFN-758",{"EARLY_PHASE1":2246,"PHASE1":2248,"PHASE2":2259,"PHASE3":2261,"PHASE4":2263,"NA":2265},{"trials":2247,"activeCount":99},[],{"trials":2249,"activeCount":99},[2250],{"nctId":2251,"briefTitle":2252,"status":425,"phases":2253,"primaryCompletion":2254,"completion":2255,"start":2256,"enrollment":1922,"conditions":2257,"interventions":2258},"NCT02800369","Study of Molecular-targeted Therapy Using Zinc Finger Nuclease in Cervical Precancerous Lesions",[87],"2017-06-10","2017-07-10","2016-12-10",[2192],[2244],{"trials":2260,"activeCount":99},[],{"trials":2262,"activeCount":99},[],{"trials":2264,"activeCount":99},[],{"trials":2266,"activeCount":99},[],{"intervention":2125,"totalTrials":117,"cells":2268},{"EARLY_PHASE1":2269,"PHASE1":2271,"PHASE2":2277,"PHASE3":2279,"PHASE4":2281,"NA":2283},{"trials":2270,"activeCount":99},[],{"trials":2272,"activeCount":99},[2273],{"nctId":2117,"briefTitle":2118,"status":425,"phases":2274,"primaryCompletion":2120,"completion":2121,"start":2122,"enrollment":527,"conditions":2275,"interventions":2276},[87],[15],[2125,2089],{"trials":2278,"activeCount":99},[],{"trials":2280,"activeCount":99},[],{"trials":2282,"activeCount":99},[],{"trials":2284,"activeCount":99},[],{"intervention":2286,"totalTrials":117,"cells":2287},"CT125A cells",{"EARLY_PHASE1":2288,"PHASE1":2306,"PHASE2":2308,"PHASE3":2310,"PHASE4":2312,"NA":2314},{"trials":2289,"activeCount":99},[2290],{"nctId":2291,"briefTitle":2292,"status":425,"phases":2293,"primaryCompletion":2294,"completion":1271,"start":2295,"enrollment":2296,"conditions":2297,"interventions":2304},"NCT04767308","Safety and Efficacy of CT125A Cells for Treatment of Relapsed\u002FRefractory CD5+ Hematopoietic Malignancies",[86],"2023-09","2021-03",18,[2298,2299,2300,2301,2302,2303],"CD5+ Relapsed\u002FRefractory Hematopoietic Malignancies","Chronic Lymphocytic Leukemia (CLL)","Mantle Cell Lymphoma (MCL)","Diffuse Large B-cell Lymphoma (DLBCL)","Follicular Lymphoma (FL)","Peripheral T-cell Lymphomas (PTCL)",[2286,2305],"Cyclophosphamide, fludarabine",{"trials":2307,"activeCount":99},[],{"trials":2309,"activeCount":99},[],{"trials":2311,"activeCount":99},[],{"trials":2313,"activeCount":99},[],{"trials":2315,"activeCount":99},[],{"intervention":2305,"totalTrials":117,"cells":2317},{"EARLY_PHASE1":2318,"PHASE1":2324,"PHASE2":2326,"PHASE3":2328,"PHASE4":2330,"NA":2332},{"trials":2319,"activeCount":99},[2320],{"nctId":2291,"briefTitle":2292,"status":425,"phases":2321,"primaryCompletion":2294,"completion":1271,"start":2295,"enrollment":2296,"conditions":2322,"interventions":2323},[86],[2298,2299,2300,2301,2302,2303],[2286,2305],{"trials":2325,"activeCount":99},[],{"trials":2327,"activeCount":99},[],{"trials":2329,"activeCount":99},[],{"trials":2331,"activeCount":99},[],{"trials":2333,"activeCount":99},[],{"intervention":2335,"totalTrials":117,"cells":2336},"MSC-derived exosomes",{"EARLY_PHASE1":2337,"PHASE1":2350,"PHASE2":2352,"PHASE3":2354,"PHASE4":2356,"NA":2358},{"trials":2338,"activeCount":99},[2339],{"nctId":2340,"briefTitle":2341,"status":425,"phases":2342,"primaryCompletion":2343,"completion":2344,"start":2345,"enrollment":2346,"conditions":2347,"interventions":2349},"NCT05808400","Safety and Efficacy of Umbilical Cord Mesenchymal Stem Cell Exosomes in Treating Chronic Cough After COVID-19",[86],"2024-02-15","2025-02-15","2023-02-15",80,[2348],"Long COVID-19 Syndrome",[2335],{"trials":2351,"activeCount":99},[],{"trials":2353,"activeCount":99},[],{"trials":2355,"activeCount":99},[],{"trials":2357,"activeCount":99},[],{"trials":2359,"activeCount":99},[],{"intervention":2361,"totalTrials":22,"cells":2362},"Dexmedetomidine",{"EARLY_PHASE1":2363,"PHASE1":2365,"PHASE2":2367,"PHASE3":2378,"PHASE4":2388,"NA":2394},{"trials":2364,"activeCount":99},[],{"trials":2366,"activeCount":99},[],{"trials":2368,"activeCount":99},[2369],{"nctId":2370,"briefTitle":2371,"status":425,"phases":2372,"primaryCompletion":2373,"completion":2373,"start":2374,"enrollment":884,"conditions":2375,"interventions":2377},"NCT03102359","Brain Protection Effect of Selective Head Cooling and Dexmedetomidine in Patients Undergoing Liver Transplantation",[88],"2019-12-31","2017-04-05",[2376],"Liver Transplant; Complications",[2361],{"trials":2379,"activeCount":99},[2380],{"nctId":2381,"briefTitle":2382,"status":425,"phases":2383,"primaryCompletion":2384,"start":900,"enrollment":706,"conditions":2385,"interventions":2387},"NCT01283412","Dexmedetomidine on Postoperative Delirium and Quality of Recovery in Geriatric Patients",[89],"2014-06",[2386],"Delirium, Postoperative",[2361],{"trials":2389,"activeCount":99},[2390],{"nctId":879,"briefTitle":880,"status":425,"phases":2391,"primaryCompletion":882,"completion":882,"start":883,"enrollment":884,"conditions":2392,"interventions":2393},[90],[886],[888,889,890,891,892,893,894],{"trials":2395,"activeCount":99},[2396,2403],{"nctId":2397,"briefTitle":2398,"status":425,"phases":2399,"primaryCompletion":1773,"completion":1503,"start":934,"enrollment":750,"conditions":2400,"interventions":2402},"NCT01704092","Dexmedetomidine's Cardiac and Cognitive Influence on Patients Undergoing Off-pump Coronary Artery Bypass Graft Surgery",[],[2401],"Coronary Artery Disease",[2361],{"nctId":2404,"briefTitle":2405,"status":436,"phases":2406,"primaryCompletion":2407,"completion":2408,"start":2057,"enrollment":1642,"conditions":2409,"interventions":2411},"NCT04767256","Intravenous Dexamethasone and Dexmedetomidine on the Analgesic Efficacy of Erector Spinae Plane Block",[91],"2021-08-22","2021-12-30",[2410,2361,753],"Dexamethasone",[2412,2361],"Dexamethasone and dexmedetomidine",{"intervention":2414,"totalTrials":95,"cells":2415},"Amoxicillin",{"EARLY_PHASE1":2416,"PHASE1":2418,"PHASE2":2420,"PHASE3":2422,"PHASE4":2424,"NA":2426},{"trials":2417,"activeCount":99},[],{"trials":2419,"activeCount":99},[],{"trials":2421,"activeCount":99},[],{"trials":2423,"activeCount":99},[],{"trials":2425,"activeCount":99},[],{"trials":2427,"activeCount":99},[2428,2441],{"nctId":2429,"briefTitle":2430,"status":425,"phases":2431,"primaryCompletion":1526,"completion":1526,"start":2432,"enrollment":2433,"conditions":2434,"interventions":2436},"NCT05189444","The Evaluation of Triple Therapy With Vonoprazan, Amoxicillin and Bismuth for Eradication of Helicobacter Pylori",[91],"2022-03-25",672,[2435],"Helicobacter Pylori Infection",[2437,2414,2438,2414,2439,2440],"Vonoprazan","Esomeprazole","Clarithromycin","Bismuth potassium citrate",{"nctId":2442,"briefTitle":2443,"status":436,"phases":2444,"primaryCompletion":2445,"completion":2446,"start":2447,"enrollment":2448,"conditions":2449,"interventions":2450},"NCT03688828","Evaluation of Saccharomyces Boulardii Combined With Standard Quadruple Therapy for Eradication of Helicobacter Pylori",[91],"2020-06-10","2020-12-31","2018-11-11",360,[2435],[2451,2438,2414,2439,2440],"Saccharomyces boulardii",{"intervention":2438,"totalTrials":95,"cells":2453},{"EARLY_PHASE1":2454,"PHASE1":2456,"PHASE2":2458,"PHASE3":2460,"PHASE4":2462,"NA":2464},{"trials":2455,"activeCount":99},[],{"trials":2457,"activeCount":99},[],{"trials":2459,"activeCount":99},[],{"trials":2461,"activeCount":99},[],{"trials":2463,"activeCount":99},[],{"trials":2465,"activeCount":99},[2466,2470],{"nctId":2429,"briefTitle":2430,"status":425,"phases":2467,"primaryCompletion":1526,"completion":1526,"start":2432,"enrollment":2433,"conditions":2468,"interventions":2469},[91],[2435],[2437,2414,2438,2414,2439,2440],{"nctId":2442,"briefTitle":2443,"status":436,"phases":2471,"primaryCompletion":2445,"completion":2446,"start":2447,"enrollment":2448,"conditions":2472,"interventions":2473},[91],[2435],[2451,2438,2414,2439,2440],{"intervention":2439,"totalTrials":95,"cells":2475},{"EARLY_PHASE1":2476,"PHASE1":2478,"PHASE2":2480,"PHASE3":2482,"PHASE4":2484,"NA":2486},{"trials":2477,"activeCount":99},[],{"trials":2479,"activeCount":99},[],{"trials":2481,"activeCount":99},[],{"trials":2483,"activeCount":99},[],{"trials":2485,"activeCount":99},[],{"trials":2487,"activeCount":99},[2488,2492],{"nctId":2429,"briefTitle":2430,"status":425,"phases":2489,"primaryCompletion":1526,"completion":1526,"start":2432,"enrollment":2433,"conditions":2490,"interventions":2491},[91],[2435],[2437,2414,2438,2414,2439,2440],{"nctId":2442,"briefTitle":2443,"status":436,"phases":2493,"primaryCompletion":2445,"completion":2446,"start":2447,"enrollment":2448,"conditions":2494,"interventions":2495},[91],[2435],[2451,2438,2414,2439,2440],{"intervention":2440,"totalTrials":95,"cells":2497},{"EARLY_PHASE1":2498,"PHASE1":2500,"PHASE2":2502,"PHASE3":2504,"PHASE4":2506,"NA":2508},{"trials":2499,"activeCount":99},[],{"trials":2501,"activeCount":99},[],{"trials":2503,"activeCount":99},[],{"trials":2505,"activeCount":99},[],{"trials":2507,"activeCount":99},[],{"trials":2509,"activeCount":99},[2510,2514],{"nctId":2429,"briefTitle":2430,"status":425,"phases":2511,"primaryCompletion":1526,"completion":1526,"start":2432,"enrollment":2433,"conditions":2512,"interventions":2513},[91],[2435],[2437,2414,2438,2414,2439,2440],{"nctId":2442,"briefTitle":2443,"status":436,"phases":2515,"primaryCompletion":2445,"completion":2446,"start":2447,"enrollment":2448,"conditions":2516,"interventions":2517},[91],[2435],[2451,2438,2414,2439,2440],{"intervention":559,"totalTrials":95,"cells":2519},{"EARLY_PHASE1":2520,"PHASE1":2522,"PHASE2":2524,"PHASE3":2530,"PHASE4":2532,"NA":2534},{"trials":2521,"activeCount":99},[],{"trials":2523,"activeCount":99},[],{"trials":2525,"activeCount":99},[2526],{"nctId":548,"briefTitle":549,"status":425,"phases":2527,"primaryCompletion":551,"completion":552,"start":553,"enrollment":11,"conditions":2528,"interventions":2529},[88],[555],[44,557,558,559,560],{"trials":2531,"activeCount":99},[],{"trials":2533,"activeCount":99},[],{"trials":2535,"activeCount":99},[2536],{"nctId":2537,"briefTitle":2538,"status":436,"phases":2539,"primaryCompletion":1383,"completion":1921,"start":2540,"enrollment":2541,"conditions":2542,"interventions":2543},"NCT01755897","A Multicenter, Prospective, Randomized Trial of Adjuvant Chemotherapy for Early-Stage Cervical Cancer Patients",[91],"2012-11",337,[31,15,21],[2544,559,559],"Paclitaxel",{"intervention":2546,"totalTrials":117,"cells":2547},"dehydrating agent, haemostatic",{"EARLY_PHASE1":2548,"PHASE1":2550,"PHASE2":2552,"PHASE3":2554,"PHASE4":2556,"NA":2558},{"trials":2549,"activeCount":99},[],{"trials":2551,"activeCount":99},[],{"trials":2553,"activeCount":99},[],{"trials":2555,"activeCount":99},[],{"trials":2557,"activeCount":99},[],{"trials":2559,"activeCount":99},[2560],{"nctId":2561,"briefTitle":2562,"status":425,"phases":2563,"primaryCompletion":1818,"completion":1017,"start":2564,"enrollment":112,"conditions":2565,"interventions":2567},"NCT00752024","Stereotactic Aspiration and Thrombolysis of Intracerebral Hemorrhage: a Prospective Controlled Study",[91],"2008-09",[2566],"Hypertensive Intracerebral Hemorrhage",[2546],{"intervention":2569,"totalTrials":117,"cells":2570},"trans-resveratrol",{"EARLY_PHASE1":2571,"PHASE1":2573,"PHASE2":2575,"PHASE3":2577,"PHASE4":2579,"NA":2581},{"trials":2572,"activeCount":99},[],{"trials":2574,"activeCount":99},[],{"trials":2576,"activeCount":99},[],{"trials":2578,"activeCount":99},[],{"trials":2580,"activeCount":99},[],{"trials":2582,"activeCount":99},[2583],{"nctId":2584,"briefTitle":2585,"status":425,"phases":2586,"primaryCompletion":2587,"completion":2587,"start":2588,"enrollment":1922,"conditions":2589,"interventions":2591},"NCT02321176","Pharmacokinetics of Trans-resveratrol Based Nutritional Supplement and Its Three Metabolites in Human Eyes and Blood",[91],"2015-04","2014-03",[2590],"Eye Disease",[2569],{"intervention":2593,"totalTrials":117,"cells":2594},"Paliperidone Palmitate",{"EARLY_PHASE1":2595,"PHASE1":2597,"PHASE2":2599,"PHASE3":2601,"PHASE4":2603,"NA":2605},{"trials":2596,"activeCount":99},[],{"trials":2598,"activeCount":99},[],{"trials":2600,"activeCount":99},[],{"trials":2602,"activeCount":99},[],{"trials":2604,"activeCount":99},[],{"trials":2606,"activeCount":99},[2607],{"nctId":2608,"briefTitle":2609,"status":425,"phases":2610,"primaryCompletion":2611,"completion":2612,"start":2613,"enrollment":2614,"conditions":2615,"interventions":2617},"NCT04064476","The Effect of Long-acting Antipsychotics on Schizophrenia Patients With Violence Risk",[],"2021-08-15","2021-09-15","2019-08-18",225,[2616],"Schizophrenia",[2593],{"intervention":2619,"totalTrials":117,"cells":2620},"conservative treatment",{"EARLY_PHASE1":2621,"PHASE1":2623,"PHASE2":2625,"PHASE3":2627,"PHASE4":2629,"NA":2631},{"trials":2622,"activeCount":99},[],{"trials":2624,"activeCount":99},[],{"trials":2626,"activeCount":99},[],{"trials":2628,"activeCount":99},[],{"trials":2630,"activeCount":99},[],{"trials":2632,"activeCount":99},[2633],{"nctId":2634,"briefTitle":2635,"status":425,"phases":2636,"primaryCompletion":1099,"completion":1099,"start":2637,"enrollment":379,"conditions":2638,"interventions":2639},"NCT00940745","Modified Stereotactic Aspiration and Thrombolysis of Intracerebral Hemorrhage:a Multi-center Controlled Study",[91],"2009-07",[2566],[2619],{"intervention":2437,"totalTrials":117,"cells":2641},{"EARLY_PHASE1":2642,"PHASE1":2644,"PHASE2":2646,"PHASE3":2648,"PHASE4":2650,"NA":2652},{"trials":2643,"activeCount":99},[],{"trials":2645,"activeCount":99},[],{"trials":2647,"activeCount":99},[],{"trials":2649,"activeCount":99},[],{"trials":2651,"activeCount":99},[],{"trials":2653,"activeCount":99},[2654],{"nctId":2429,"briefTitle":2430,"status":425,"phases":2655,"primaryCompletion":1526,"completion":1526,"start":2432,"enrollment":2433,"conditions":2656,"interventions":2657},[91],[2435],[2437,2414,2438,2414,2439,2440],{"intervention":2659,"totalTrials":117,"cells":2660},"Insulin",{"EARLY_PHASE1":2661,"PHASE1":2663,"PHASE2":2665,"PHASE3":2667,"PHASE4":2669,"NA":2671},{"trials":2662,"activeCount":99},[],{"trials":2664,"activeCount":99},[],{"trials":2666,"activeCount":99},[],{"trials":2668,"activeCount":99},[],{"trials":2670,"activeCount":99},[],{"trials":2672,"activeCount":99},[2673],{"nctId":2674,"briefTitle":2675,"status":436,"phases":2676,"primaryCompletion":899,"completion":899,"start":2677,"enrollment":2678,"conditions":2679,"interventions":2681},"NCT02006836","Glycemic Responses to Majia Pomelos in Type 2 Diabetic Patients",[91],"2013-01",59,[2680],"Diabetes",[2659,2682],"met or diet",{"intervention":2682,"totalTrials":117,"cells":2684},{"EARLY_PHASE1":2685,"PHASE1":2687,"PHASE2":2689,"PHASE3":2691,"PHASE4":2693,"NA":2695},{"trials":2686,"activeCount":99},[],{"trials":2688,"activeCount":99},[],{"trials":2690,"activeCount":99},[],{"trials":2692,"activeCount":99},[],{"trials":2694,"activeCount":99},[],{"trials":2696,"activeCount":99},[2697],{"nctId":2674,"briefTitle":2675,"status":436,"phases":2698,"primaryCompletion":899,"completion":899,"start":2677,"enrollment":2678,"conditions":2699,"interventions":2700},[91],[2680],[2659,2682],{"intervention":2702,"totalTrials":117,"cells":2703},"consolidation with ASCT",{"EARLY_PHASE1":2704,"PHASE1":2706,"PHASE2":2708,"PHASE3":2710,"PHASE4":2712,"NA":2714},{"trials":2705,"activeCount":99},[],{"trials":2707,"activeCount":99},[],{"trials":2709,"activeCount":99},[],{"trials":2711,"activeCount":99},[],{"trials":2713,"activeCount":99},[],{"trials":2715,"activeCount":99},[2716],{"nctId":2717,"briefTitle":2718,"status":436,"phases":2719,"primaryCompletion":2720,"completion":2721,"start":2722,"enrollment":2723,"conditions":2724,"interventions":2726},"NCT06149390","ASCT Versus Chemotherapy as First-Line Consolidation Therapy inT-Cell Lymphoma",[],"2022-01-01","2023-07-01","2014-01-01",347,[2725],"T-cell Lymphoma Adults",[2702],{"intervention":2728,"totalTrials":117,"cells":2729},"Ulinastatin",{"EARLY_PHASE1":2730,"PHASE1":2732,"PHASE2":2734,"PHASE3":2736,"PHASE4":2738,"NA":2740},{"trials":2731,"activeCount":99},[],{"trials":2733,"activeCount":99},[],{"trials":2735,"activeCount":99},[],{"trials":2737,"activeCount":99},[],{"trials":2739,"activeCount":99},[],{"trials":2741,"activeCount":99},[2742],{"nctId":2743,"briefTitle":2744,"status":425,"phases":2745,"primaryCompletion":2746,"completion":2747,"start":2345,"enrollment":2346,"conditions":2748,"interventions":2750},"NCT05716256","Effect of Ulinastatin on the Action of NDMRs (Rocuronium \u002F Cisatracurium)",[91],"2023-06-15","2023-06-25",[2749],"Nondepolarising Muscle Relaxants",[2728],{"intervention":2752,"totalTrials":117,"cells":2753},"LONGEVINEX",{"EARLY_PHASE1":2754,"PHASE1":2756,"PHASE2":2758,"PHASE3":2760,"PHASE4":2762,"NA":2764},{"trials":2755,"activeCount":99},[],{"trials":2757,"activeCount":99},[],{"trials":2759,"activeCount":99},[],{"trials":2761,"activeCount":99},[],{"trials":2763,"activeCount":99},[],{"trials":2765,"activeCount":99},[2766],{"nctId":2767,"briefTitle":2768,"status":425,"phases":2769,"primaryCompletion":440,"completion":440,"start":2770,"enrollment":2771,"conditions":2772,"interventions":2773},"NCT02321189","The Effect of Resveratrol Based Nutritional Supplement on Choroidal Thickness",[91],"2014-10",34,[2590],[2752],{"intervention":2451,"totalTrials":117,"cells":2775},{"EARLY_PHASE1":2776,"PHASE1":2778,"PHASE2":2780,"PHASE3":2782,"PHASE4":2784,"NA":2786},{"trials":2777,"activeCount":99},[],{"trials":2779,"activeCount":99},[],{"trials":2781,"activeCount":99},[],{"trials":2783,"activeCount":99},[],{"trials":2785,"activeCount":99},[],{"trials":2787,"activeCount":99},[2788],{"nctId":2442,"briefTitle":2443,"status":436,"phases":2789,"primaryCompletion":2445,"completion":2446,"start":2447,"enrollment":2448,"conditions":2790,"interventions":2791},[91],[2435],[2451,2438,2414,2439,2440],{"intervention":2793,"totalTrials":117,"cells":2794},"Influenza vaccination",{"EARLY_PHASE1":2795,"PHASE1":2797,"PHASE2":2799,"PHASE3":2801,"PHASE4":2803,"NA":2805},{"trials":2796,"activeCount":99},[],{"trials":2798,"activeCount":99},[],{"trials":2800,"activeCount":99},[],{"trials":2802,"activeCount":99},[],{"trials":2804,"activeCount":99},[],{"trials":2806,"activeCount":99},[2807],{"nctId":2808,"briefTitle":2809,"status":436,"phases":2810,"primaryCompletion":2373,"completion":2811,"start":2812,"enrollment":112,"conditions":2813,"interventions":2816},"NCT04188483","Effect of Selenium Supplementation on Influenza Vaccination",[91],"2020-02-01","2019-10-15",[2814,2815],"Selenium Supplementation","Influenza Vaccination",[2793],{"intervention":2544,"totalTrials":117,"cells":2818},{"EARLY_PHASE1":2819,"PHASE1":2821,"PHASE2":2823,"PHASE3":2825,"PHASE4":2827,"NA":2829},{"trials":2820,"activeCount":99},[],{"trials":2822,"activeCount":99},[],{"trials":2824,"activeCount":99},[],{"trials":2826,"activeCount":99},[],{"trials":2828,"activeCount":99},[],{"trials":2830,"activeCount":99},[2831],{"nctId":2537,"briefTitle":2538,"status":436,"phases":2832,"primaryCompletion":1383,"completion":1921,"start":2540,"enrollment":2541,"conditions":2833,"interventions":2834},[91],[31,15,21],[2544,559,559],{"intervention":2412,"totalTrials":117,"cells":2836},{"EARLY_PHASE1":2837,"PHASE1":2839,"PHASE2":2841,"PHASE3":2843,"PHASE4":2845,"NA":2847},{"trials":2838,"activeCount":99},[],{"trials":2840,"activeCount":99},[],{"trials":2842,"activeCount":99},[],{"trials":2844,"activeCount":99},[],{"trials":2846,"activeCount":99},[],{"trials":2848,"activeCount":99},[2849],{"nctId":2404,"briefTitle":2405,"status":436,"phases":2850,"primaryCompletion":2407,"completion":2408,"start":2057,"enrollment":1642,"conditions":2851,"interventions":2852},[91],[2410,2361,753],[2412,2361],{"intervention":2854,"totalTrials":117,"cells":2855},"Upper Limit Nutrition Support Therapy",{"EARLY_PHASE1":2856,"PHASE1":2858,"PHASE2":2860,"PHASE3":2862,"PHASE4":2864,"NA":2866},{"trials":2857,"activeCount":99},[],{"trials":2859,"activeCount":99},[],{"trials":2861,"activeCount":99},[],{"trials":2863,"activeCount":99},[],{"trials":2865,"activeCount":99},[],{"trials":2867,"activeCount":99},[2868],{"nctId":2869,"briefTitle":2870,"status":425,"phases":2871,"primaryCompletion":2872,"completion":2872,"start":2588,"enrollment":2873,"conditions":2874,"interventions":2876},"NCT02102659","Biological Assessment of Clinical Nutrition and Its Application",[91],"2015-11",167,[2875],"Malnutrition",[2854,2877],"Formula Nutrition Support Therapy",{"intervention":2877,"totalTrials":117,"cells":2879},{"EARLY_PHASE1":2880,"PHASE1":2882,"PHASE2":2884,"PHASE3":2886,"PHASE4":2888,"NA":2890},{"trials":2881,"activeCount":99},[],{"trials":2883,"activeCount":99},[],{"trials":2885,"activeCount":99},[],{"trials":2887,"activeCount":99},[],{"trials":2889,"activeCount":99},[],{"trials":2891,"activeCount":99},[2892],{"nctId":2869,"briefTitle":2870,"status":425,"phases":2893,"primaryCompletion":2872,"completion":2872,"start":2588,"enrollment":2873,"conditions":2894,"interventions":2895},[91],[2875],[2854,2877],{"intervention":2897,"totalTrials":117,"cells":2898},"There is no intervention in this study.",{"EARLY_PHASE1":2899,"PHASE1":2901,"PHASE2":2903,"PHASE3":2905,"PHASE4":2907,"NA":2909},{"trials":2900,"activeCount":99},[],{"trials":2902,"activeCount":99},[],{"trials":2904,"activeCount":99},[],{"trials":2906,"activeCount":99},[],{"trials":2908,"activeCount":99},[],{"trials":2910,"activeCount":99},[2911],{"nctId":2912,"briefTitle":2913,"status":425,"phases":2914,"primaryCompletion":2915,"completion":2916,"start":2917,"enrollment":1642,"conditions":2918,"interventions":2922},"NCT05009134","Influences of Allergic Rhinitis and Allergen Immunotherapy on SARS-CoV-2 Vaccination",[],"2022-03-20","2022-04-30","2021-06-04",[2919,2920,2921],"Allergic Rhinitis","Allergen Immunotherapy","SARS-CoV-2",[2897],{"intervention":2924,"totalTrials":117,"cells":2925},"trail cohort",{"EARLY_PHASE1":2926,"PHASE1":2928,"PHASE2":2930,"PHASE3":2932,"PHASE4":2934,"NA":2936},{"trials":2927,"activeCount":99},[],{"trials":2929,"activeCount":99},[],{"trials":2931,"activeCount":99},[],{"trials":2933,"activeCount":99},[],{"trials":2935,"activeCount":99},[],{"trials":2937,"activeCount":99},[2938],{"nctId":2939,"briefTitle":2940,"status":436,"phases":2941,"primaryCompletion":2942,"completion":2943,"start":2722,"enrollment":2944,"conditions":2945,"interventions":2948},"NCT03376945","Application of n-3 Fatty to Patient of Jaundice",[],"2017-10-01","2017-10-15",106,[2946,2947],"Obstructive Jaundice","Surgical Procedure, Unspecified",[2924,2949],"control cohort",{"intervention":2949,"totalTrials":117,"cells":2951},{"EARLY_PHASE1":2952,"PHASE1":2954,"PHASE2":2956,"PHASE3":2958,"PHASE4":2960,"NA":2962},{"trials":2953,"activeCount":99},[],{"trials":2955,"activeCount":99},[],{"trials":2957,"activeCount":99},[],{"trials":2959,"activeCount":99},[],{"trials":2961,"activeCount":99},[],{"trials":2963,"activeCount":99},[2964],{"nctId":2939,"briefTitle":2940,"status":436,"phases":2965,"primaryCompletion":2942,"completion":2943,"start":2722,"enrollment":2944,"conditions":2966,"interventions":2967},[],[2946,2947],[2924,2949]]